A61K 31/502 (2006.01)
A61K 31/407 (2006.01)
A61P 19/02 (2006.01)
A61P 29/02 (2006.01)

INHIBITORS OF BRUTON'S TYROSINE KINASE

Abstract: This application discloses compounds according to generic Formula (I): wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.
INHIBITORS OF BRUTON'S TYROSINE KINASE

FIELD OF THE INVENTION

The present invention relates to the use of novel compounds which inhibit Btk and are useful for the treatment of auto-immune and inflammatory diseases caused by aberrant B-cell activation.

BACKGROUND OF THE INVENTION

Protein kinases constitute one of the largest families of human enzymes and regulate many different signaling processes by adding phosphate groups to proteins (T. Hunter, Cell 1987 50:823-829). Specifically, tyrosine kinases phosphorylate proteins on the phenolic moiety of tyrosine residues. The tyrosine kinase family includes members that control cell growth, migration, and differentiation. Abnormal kinase activity has been implicated in a variety of human diseases including cancers, autoimmune and inflammatory diseases. Since protein kinases are among the key regulators of cell signaling they provide a target to modulate cellular function with small molecular kinase inhibitors and thus make good drug design targets. In addition to treatment of kinase-mediated disease processes, selective and efficacious inhibitors of kinase activity are also useful for investigation of cell signaling processes and identification of other cellular targets of therapeutic interest.

There is good evidence that B-cells play a key role in the pathogenesis of autoimmune and/or inflammatory disease. Protein-based therapeutics that deplete B cells such as Rituxan are effective against autoantibody-driven inflammatory diseases such as rheumatoid arthritis (Rastetter et al. Annu Rev Med 2004 55:477). Therefore inhibitors of the protein kinases that play a role in B-cell activation should be useful therapeutics for B-cell mediated disease pathology such as autoantibody production.

Signaling through the B-cell receptor (BCR) controls a range of B-cell responses including proliferation and differentiation into mature antibody producing cells. The BCR is a key regulatory point for B-cell activity and aberrant signaling can cause deregulated B-cell proliferation and formation of pathogenic autoantibodies that lead to multiple autoimmune and/or inflammatory diseases. Bruton's Tyrosine Kinase (Btk) is a non-BCR associated kinase
that is membrane proximal and immediately downstream from BCR. Lack of Btk has been shown to block BCR signaling and therefore inhibition of Btk could be a useful therapeutic approach to block B-cell mediated disease processes.

Btk is a member of the Tec family of tyrosine kinases, and has been shown to be a critical regulator of early B-cell development and mature B-cell activation and survival (Khan et al. *Immunity* 1995 3:283; Ellmeier et al. *J. Exp. Med.* 2000 192:1611). Mutation of Btk in humans leads to the condition X-linked agammaglobulinemia (XLA) (reviewed in Rosen et al. *New Eng. J. Med.* 1995 333:431 and Lindvall et al. *Immunol. Rev.* 2005 203:200). These patients are immunocompromised and show impaired maturation of B-cells, decreased immunoglobulin and peripheral B-cell levels, diminished T-cell independent immune responses as well as attenuated calcium mobilization following BCR stimulation.

Evidence for a role for Btk in autoimmune and inflammatory diseases has also been provided by Btk-deficient mouse models. In preclinical murine models of systemic lupus erythematosus (SLE), Btk-deficient mice show marked amelioration of disease progression. In addition, Btk-deficient mice are resistant to collagen-induced arthritis (Jansson and Holmdahl *Clin. Exp. Immunol.* 1993 94:459). A selective Btk inhibitor has been demonstrated dose-dependent efficacy in a mouse arthritis model (Z. Pan et al., *Chem. Med Chem.* 2007 2:58-61).

Btk is also expressed by cells other than B-cells that may be involved in disease processes. For example, Btk is expressed by mast cells and Btk-deficient bone marrow derived mast cells demonstrate impaired antigen induced degranulation (Iwaki et al. *J. Biol. Chem.* 2005 280:40261). This shows Btk could be useful to treat pathological mast cells responses such as allergy and asthma. Also monocytes from XLA patients, in which Btk activity is absent, show decreased TNF alpha production following stimulation (Horwood et al. *J Exp Med* 197:1603, 2003). Therefore TNF alpha mediated inflammation could be modulated by small molecular Btk inhibitors. Also, Btk has been reported to play a role in apoptosis (Islam and Smith *Immunol. Rev.* 2000 178:49,) and thus Btk inhibitors would be useful for the treatment of certain B-cell lymphomas and leukemias (Feldhahn et al. *J. Exp. Med.* 2005 201:1837).

**SUMMARY OF THE INVENTION**

The present application provides the Btk inhibitor compounds of Formula I, methods of use thereof, as described herein below:
The application provides a compound of Formula I,

wherein:

A is unsaturated or partially saturated monocyclic or bicyclic heteroaryl or phenyl, optionally substituted with one or more A';

A' is halo, lower alkyl, or oxo;

each R¹ is independently halo, hydroxyl lower alkyl, or lower alkyl;

m is 0, 1, or 2;

R² is methyl pyrazolyl;

n is 0 or 1; and

X is a bond, CH₂ or NHC(=0);

or a pharmaceutically acceptable salt thereof.
The application provides a compound of Formula I,

\[
\begin{array}{c}
\text{I} \\
\end{array}
\]

wherein:

A is unsaturated or partially saturated monocyclic or bicyclic heteroaryl or phenyl, optionally substituted with one or more A';

A' is halo, lower alkyl, or oxo;

each \( R^1 \) is independently halo, hydroxyl loweralkyl, or lower alkyl;

m is 0, 1, or 2;

\( R^2 \) is methyl pyrazolyl;

n is 0 or 1; and

X is \( \text{CH}_2 \) or NHC(=0);

or a pharmaceutically acceptable salt thereof.

The application provides a method for treating an inflammatory and/or autoimmune condition comprising administering to a patient in need thereof a therapeutically effective amount of the compound of Formula I.

The application provides a pharmaceutical composition comprising the compound of Formula I, admixed with at least one pharmaceutically acceptable carrier, excipient or diluent.
DETAILED DESCRIPTION OF THE INVENTION

Definitions

The phrase "a" or "an" entity as used herein refers to one or more of that entity; for example, a compound refers to one or more compounds or at least one compound. As such, the terms "a" (or "an"), "one or more", and "at least one" can be used interchangeably herein.

The phrase "as defined herein above" refers to the broadest definition for each group as provided in the Summary of the Invention or the broadest claim. In all other embodiments provided below, substituents which can be present in each embodiment and which are not explicitly defined retain the broadest definition provided in the Summary of the Invention.

As used in this specification, whether in a transitional phrase or in the body of the claim, the terms "comprise(s)" and "comprising" are to be interpreted as having an open-ended meaning. That is, the terms are to be interpreted synonymously with the phrases "having at least" or "including at least". When used in the context of a process, the term "comprising" means that the process includes at least the recited steps, but may include additional steps. When used in the context of a compound or composition, the term "comprising" means that the compound or composition includes at least the recited features or components, but may also include additional features or components.

As used herein, unless specifically indicated otherwise, the word "or" is used in the "inclusive" sense of "and/or" and not the "exclusive" sense of "either/or".

The term "independently" is used herein to indicate that a variable is applied in any one instance without regard to the presence or absence of a variable having that same or a different definition within the same compound. Thus, in a compound in which R" appears twice and is defined as "independently carbon or nitrogen", both R"s can be carbon, both R"s can be nitrogen, or one R" can be carbon and the other nitrogen.

When any variable occurs more than one time in any moiety or formula depicting and describing compounds employed or claimed in the present invention, its definition on each occurrence is independent of its definition at every other occurrence. Also, combinations of substituents and/or variables are permissible only if such compounds result in stable compounds.
The symbols “*” at the end of a bond or " ———" drawn through a bond each refer to the point of attachment of a functional group or other chemical moiety to the rest of the molecule of which it is a part. Thus, for example:

\[
\text{MeC(=0)OR}^4 \text{ wherein } R^4 = \text{—} < \text{ or —} \text{ —} < \text{ } \Rightarrow \text{MeC(=0)0— < [ ] .}
\]

A bond drawn into ring system (as opposed to connected at a distinct vertex) indicates that the bond may be attached to any of the suitable ring atoms.

The term "optional" or "optionally" as used herein means that a subsequently described event or circumstance may, but need not, occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not. For example, "optionally substituted" means that the optionally substituted moiety may incorporate a hydrogen atom or a substituent.

The phrase "optional bond" means that the bond may or may not be present, and that the description includes single, double, or triple bonds. If a substituent is designated to be a "bond" or "absent", the atoms linked to the substituents are then directly connected.

The term "about" is used herein to mean approximately, in the region of, roughly, or around. When the term "about" is used in conjunction with a numerical range, it modifies that range by extending the boundaries above and below the numerical values set forth. In general, the term "about" is used herein to modify a numerical value above and below the stated value by a variance of 20%.

Certain compounds of Formulae I may exhibit tautomerism. Tautomeric compounds can exist as two or more interconvertable species. Prototropic tautomers result from the migration of a covalently bonded hydrogen atom between two atoms. Tautomers generally exist in equilibrium and attempts to isolate an individual tautomers usually produce a mixture whose chemical and physical properties are consistent with a mixture of compounds. The position of the equilibrium is dependent on chemical features within the molecule. For example, in many aliphatic aldehydes and ketones, such as acetaldehyde, the keto form predominates while; in phenols, the enol form predominates. Common prototropic tautomers include keto/enol (\(-\text{C(=0)-CH-} \Leftrightarrow \text{-C(-OH)=CH-}\)), amide/imidic acid (\(-\text{C(=0)-NH-} \overset{\equiv}{\sim} \text{-C(-OH)=N-}\)) and amidine (\(-\text{C(=NR)-NH-} \overset{\equiv}{\sim} \text{-C(-OH)}\)).
C(-NHR)=N-) tautomers. The latter two are particularly common in heteroaryl and heterocyclic rings and the present invention encompasses all tautomeric forms of the compounds.

Technical and scientific terms used herein have the meaning commonly understood by one of skill in the art to which the present invention pertains, unless otherwise defined. Reference is made herein to various methodologies and materials known to those of skill in the art. Standard reference works setting forth the general principles of pharmacology include Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th Ed., McGraw Hill Companies Inc., New York (2001). Any suitable materials and/or methods known to those of skill can be utilized in carrying out the present invention. However, preferred materials and methods are described. Materials, reagents and the like to which reference are made in the following description and examples are obtainable from commercial sources, unless otherwise noted.

The definitions described herein may be appended to form chemically-relevant combinations, such as "heteroalkylaryl", "haloalkylheteroaryl", "arylalkylheterocyclyl", "alkylcarbonyl", "alkoxyalkyl", and the like. When the term "alkyl" is used as a suffix following another term, as in "phenylalkyl", or "hydroxyalkyl", this is intended to refer to an alkyl group, as defined above, being substituted with one to two substituents selected from the other specifically-named group. Thus, for example, "phenylalkyl" refers to an alkyl group having one to two phenyl substituents, and thus includes benzyl, phenylethyl, and biphenyl. An "alkylaminoalkyl" is an alkyl group having one to two alkylamino substituents. "Hydroxyalkyl" includes 2-hydroxyethyl, 2-hydroxypropyl, 1-(hydroxymethyl)-2-methylpropyl, 2-hydroxybutyl, 2,3-dihydroxybutyl, 2-(hydroxymethyl), 3-hydroxypropyl, and so forth. Accordingly, as used herein, the term "hydroxyalkyl" is used to define a subset of heteroalkyl groups defined below. The term - (ar)alkyl refers to either an unsubstituted alkyl or an aralkyl group. The term (het)aryl refers to either an aryl or a heteroaryl group.

The term "spirocycloalkyl", as used herein, means a spirocyclic cycloalkyl group, such as, for example, spiro[3.3]heptane. The term spiroheterocycloalkyl, as used herein, means a spirocyclic heterocycloalkyl, such as, for example, 2,6-diaza spiro[3.3]heptane.

The term "acyl" as used herein denotes a group of formula -C(=0)R wherein R is hydrogen or lower alkyl as defined herein. The term or "alkylcarbonyl" as used herein denotes a group of formula C(=0)R wherein R is alkyl as defined herein. The term C_{1-6} acyl refers to a group - C(=0)R contain 6 carbon atoms. The term "arylcarbonyl" as used herein means a group of
formula C(=0)R wherein R is an aryl group; the term "benzoyl" as used herein an "arylcarbonyl" group wherein R is phenyl.

The term "ester" as used herein denotes a group of formula -C(=0)OR wherein R is lower alkyl as defined herein.

The term "alkyl" as used herein denotes an unbranched or branched chain, saturated, monovalent hydrocarbon residue containing 1 to 10 carbon atoms. The term "lower alkyl" denotes a straight or branched chain hydrocarbon residue containing 1 to 6 carbon atoms. "C₁₋₁₀ alkyl" as used herein refers to an alkyl composed of 1 to 10 carbons. Examples of alkyl groups include, but are not limited to, lower alkyl groups include methyl, ethyl, propyl, /-propyl, n-butyl, /-butyl, /-butyl or pentyl, isopentyl, neopentyl, hexyl, heptyl, and octyl.

When the term "alkyl" is used as a suffix following another term, as in "phenylalkyl", or "hydroxyalkyl", this is intended to refer to an alkyl group, as defined above, being substituted with one to two substituents selected from the other specifically-named group. Thus, for example, "phenylalkyl" denotes the radical R'R"-, wherein R' is a phenyl radical, and R" is an alkylene radical as defined herein with the understanding that the attachment point of the phenylalkyl moiety will be on the alkylene radical. Examples of arylalkyl radicals include, but are not limited to, benzyl, phenylethyl, 3-phenylpropyl. The terms "arylalkyl" or "aralkyl" are interpreted similarly except R is an aryl radical. The terms "(het)arylalkyl" or "(het)aralkyl" are interpreted similarly except R is optionally an aryl or a heteroaryl radical.

The terms "haloalkyl" or "halo-lower alkyl" or "lower haloalkyl" refers to a straight or branched chain hydrocarbon residue containing 1 to 6 carbon atoms wherein one or more carbon atoms are substituted with one or more halogen atoms.

The term "alkylene" or "alkylenyl" as used herein denotes a divalent saturated linear hydrocarbon radical of 1 to 10 carbon atoms (e.g., (CH₂)ₙ) or a branched saturated divalent hydrocarbon radical of 2 to 10 carbon atoms (e.g., -CHMe- or -CH₂CH(/-Pr)CH₂-), unless otherwise indicated. Except in the case of methylene, the open valences of an alkylene group are not attached to the same atom. Examples of alkylene radicals include, but are not limited to, methylene, ethylene, propylene, 2-methyl-propylene, 1,1-dimethyl-ethylene, butylene, 2-ethylbutylene.
The term "alkoxy" as used herein means an -O-alkyl group, wherein alkyl is as defined above such as methoxy, ethoxy, n-propyloxy, i-propyloxy, n-butyloxy, i-butyloxy, t-butyloxy, pentyloxy, hexyloxy, including their isomers. "Lower alkoxy" as used herein denotes an alkoxy group with a "lower alkyl" group as previously defined. "C_{1-10} alkoxy" as used herein refers to an-O-alkyl wherein alkyl is C_{1-10}.

The term "PCy_3" refers to a phosphine trisubstituted with three cyclic moieties.

The terms "haloalkoxy" or "halo-lower alkoxy" or "lower haloalkoxy" refers to a lower alkoxy group, wherein one or more carbon atoms are substituted with one or more halogen atoms.

The term "hydroxyalkyl" as used herein denotes an alkyl radical as herein defined wherein one to three hydrogen atoms on different carbon atoms is/are replaced by hydroxy groups.

The terms "alkylsulfonyl" and "arylsulfonyl" as used herein refers to a group of formula -S(=0)_{2}R wherein R is alkyl or aryl respectively and alkyl and aryl are as defined herein. The term "heteroalkylsulfonyl" as used herein refers herein denotes a group of formula -S(=0)_{2}R wherein R is "heteroalkyl" as defined herein.

The terms "alkylsulfonylamino" and "arylsulfonylamino" as used herein refers to a group of formula -NR'S(=0)_{2}R wherein R is alkyl or aryl respectively, R' is hydrogen or C_{1-3} alkyl, and alkyl and aryl are as defined herein.

The term "cycloalkyl" as used herein refers to a saturated carbocyclic ring containing 3 to 8 carbon atoms, i.e. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl. "C_{3-7} cycloalkyl" as used herein refers to a cycloalkyl composed of 3 to 7 carbons in the carbocyclic ring.

The term "carboxy-alkyl" as used herein refers to an alkyl moiety wherein one, hydrogen atom has been replaced with a carboxyl with the understanding that the point of attachment of the heteroalkyl radical is through a carbon atom. The term "carboxy" or "carboxyl" refers to a -CO_{2}H moiety.

The term "heteroaryl" or "heteroaromatic" as used herein means a monocyclic or bicyclic radical of 5 to 12 ring atoms having at least one aromatic or partially unsaturated ring containing four to eight atoms per ring, incorporating one or more N, O, or S heteroatoms, the remaining ring atoms being carbon, with the understanding that the attachment point of the heteroaryl radical
will be on an aromatic or partially unsaturated ring. As well known to those skilled in the art, heteroaryl rings have less aromatic character than their all-carbon counter parts. Thus, for the purposes of the invention, a heteroaryl group need only have some degree of aromatic character. Examples of heteroaryl moieties include monocyclic aromatic heterocycles having 5 to 6 ring atoms and 1 to 3 heteroatoms include, but is not limited to, pyridinyl, pyrimidinyl, pyrazinyl, oxazinyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, 4,5-Dihydro-oxazolyl, 5,6-Dihydro-4H-[1,3]oxazolyl, isoxazole, thiazole, isothiazole, triazine, thiadiazole and oxadiazoline which can optionally be substituted with one or more, preferably one or two substituents selected from hydroxy, cyano, alkyl, alkoxy, thio, lower haloalkoxy, alkylthio, halo, lower haloalkyl, alkylsulfonyl, alkyloxysulfanyl, halogen, amino, alkylamino, dialkylamino, aminoalkyl, alkyloxynalkyl, and dialkylamino alkyl, nitro, alkoxycarbonyl and carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, aryloxycarbamoyl, alkyloxycarbonylamino and aryloxycarbonylamino. Examples of bicyclic moieties include, but are not limited to, quinolinyl, isoquinolinyl, benzofuryl, benzoazepinyl, benzoazolyl, benzisoxazolyl, benzthiazolyl, napththiopyran, 5,6,7,8-Tetrahydro-[1,6]naphthyridinyl, and benzisothiazole. Bicyclic moieties can be optionally substituted on either ring, however the point of attachment is on a ring containing a heteroatom.

The term "heterocyclic", "heterocycloalkyl" or "heterocycle" as used herein denotes a monovalent saturated cyclic radical, consisting of one or more rings, preferably one to two rings, including spirocyclic ring systems, of three to eight atoms per ring, incorporating one or more ring heteroatoms (chosen from N,0 or S(0)o−2), and which can optionally be independently substituted with one or more, preferably one or two substituents selected from hydroxy, oxo, cyano, lower alkyl, lower alkoxy, lower haloalkoxy, alkylthio, halo, lower haloalkyl, hydroxyalkyl, nitro, alkoxycarbonyl, amino, alkylamino, alkylsulfonyl, hydroxyalkyl, nitro, alkoxycarbonyl, amino, alkylamino, alkylsulfonyl, aryloxycarbonylamino, alkyloxycarbonylamino, and ionic forms thereof, unless otherwise indicated. Examples of heterocyclic radicals include, but are not limited to, morpholinyl, piperazinyl, piperidinyl, azetidinyl, pyrrolidinyl, hexahydroazepinyl, oxetanyle, tetrahydrofuranyl, tetrahydrothiophenyl, oxazolidinyl, thiazolidinyl, isoxazolidinyl, tetrahydropyranly, thiomorpholinyl, quinuclidinyl and imidazolinyl, and ionic forms thereof. Examples may also be bicyclic, such as, for example, 3,8-diaza-bicyclo[3.2.1]octane, 2,5-diaza-bicyclo[2.2.2]octane, or octahydro-pyrazino[2,1-c][1,4]oxazine.
Inhibitors of Btk

The application provides a compound of Formula I,

![Chemical Structure](image)

wherein:

5. A is unsaturated or partially saturated monocyclic or bicyclic heteroaryl or phenyl, optionally substituted with one or more A·;

   A· is halo, lower alkyl, or oxo;

   each R1 is independently halo, hydroxyl lower alkyl, or lower alkyl;

   m is 0, 1, or 2;

10. R2 is methyl pyrazolyl;

   n is 0 or 1; and

   X is a bond, CH₂ or NHC(=0);

or a pharmaceutically acceptable salt thereof.
The application provides a compound of Formula I,

\[
\begin{align*}
\text{I} & \quad \text{wherein:} \\
A & \text{is unsaturated or partially saturated monocyclic or bicyclic heteroaryl or phenyl, optionally substituted with one or more } A' \\
A' & \text{is halo, lower alkyl, or oxo;} \\
each R^1 & \text{is independently halo, hydroxyl loweralkyl, or lower alkyl;} \\
m & \text{is 0, 1, or 2;} \\
R^2 & \text{is methyl pyrazolyl;} \\
n & \text{is 0 or 1; and} \\
X & \text{is } CH_2 \text{ or } NHC(=0); \\
or a pharmaceutically acceptable salt thereof. \\
\end{align*}
\]

Further it is to be understood that every embodiment relating to a specific residue X, A, A’, R^1, and R^2 as disclosed herein may be combined with any other embodiment relating to another residue X, A, A’, R^1, and R^2 as disclosed herein.

The application provides a compound of Formula I, wherein X is CH₂.

The application provides a compound of Formula I, wherein n is 1.
The application provides a compound of Formula I, wherein n is 0.

The application provides a compound of Formula I, wherein X is CH₂ and n is 1.

The application provides a compound of Formula I, wherein X is CH₂ and n is 0.

The application provides a compound of Formula I, wherein X is NHC(=0) and n is 0.

The application provides any of the above compounds of Formula I, wherein m is 1.

The application provides any of the above compounds of Formula I, wherein R₁ is F.

The application provides any of the above compounds of Formula I, wherein R₁ is hydroxyl lower alkyl.

The application provides a compound of Formula I, wherein m is 2.

The application provides the above compound of Formula I, wherein both R₁ are F or one R₁ is F and the other is hydroxyl lower alkyl.

The application provides a compound of Formula I, wherein m is 0.

The application provides any of the above compounds of Formula I, wherein A is unsaturated or partially saturated monocyclic heteroaryl, optionally substituted with one or more A'.

The application provides any of the above compounds of Formula I, wherein A is unsaturated or partially saturated bicyclic heteroaryl, optionally substituted with one or more A'.

The application provides the above compound of Formula I, wherein A is substituted with F, oxo, and tert-butyl.

The application provides any of the above compounds of Formula I, wherein X=CH₂ and n is 0.

The application provides any of the above compounds of Formula I, wherein X=CH₂, n is 0 and A is unsaturated or partially saturated bicyclic heteroaryl, optionally substituted with one or more A'.

The application provides any of the above compounds of Formula I, wherein X=CH₂, n is 0, A is unsaturated or partially saturated bicyclic heteroaryl, optionally substituted with one or more A' and A' is lower alkyl, halo or oxo.
The application provides any of the above compounds of Formula I, wherein X=CH₂, n is 0, A is unsaturated or partially saturated bicyclic heteroaryl, optionally substituted with one or more A' and A' is tert-butyl, F or oxo.

The application provides any of the above compounds of Formula I, wherein X=CH₂, n is 0, A is unsaturated or partially saturated bicyclic heteroaryl, optionally substituted with one or more A', A' is tert-butyl, F or oxo and R¹ is halo or hydroxyl lower alkyl.

The application provides any of the above compounds of Formula I, wherein X=CH₂, n is 0, A is unsaturated or partially saturated bicyclic heteroaryl, optionally substituted with one or more A', A' is tert-butyl, F or oxo and R¹ is F or hydroxymethyl.

The application provides any of the above compounds of Formula I, wherein X=CH₂, n is 0, A is unsaturated or partially saturated bicyclic heteroaryl, optionally substituted with one or more A', A' is tert-butyl, F or oxo, R¹ is F or hydroxymethyl and m=1.

The application provides any of the above compounds of Formula I, wherein X=CH₂, n is 0, A is unsaturated or partially saturated bicyclic heteroaryl, optionally substituted with one or more A', A' is tert-butyl, F or oxo, R¹ is F or hydroxymethyl and m=0 or 2.

The application provides any of the above compounds of Formula I, wherein X=CH₂, n is 0, A is phthalazine, optionally substituted with one or more A', A' is tert-butyl, F or oxo, R¹ is F or hydroxymethyl and m=1.

The application provides any of the above compounds of Formula I, wherein X is a bond, n is 0, A is unsaturated or partially saturated bicyclic heteroaryl, optionally substituted with one or more A', A' is lower alkyl, halo or oxo, R¹ is F or hydroxyl lower alkyl, and m=1.

The application provides any of the above compounds of Formula I, wherein X is a bond, n is 0, A is unsaturated or partially saturated bicyclic heteroaryl, optionally substituted with one or more A', A' is tert-butyl, F or oxo, R¹ is F or hydroxymethyl and m=1.

The application provides any of the above compounds of Formula I, wherein X is a bond, n is 0, A is phthalazine, optionally substituted with one or more A', A' is tert-butyl, F or oxo, R¹ is F or hydroxymethyl and m=1.
The application provides any of the above compounds of Formula I, wherein X=NHC(=0), n is 0, A is phenyl, optionally substituted with one or more A’, A’ is lower alkyl, halo or oxo, R¹ is lower alkyl and m=1.

The application provides any of the above compounds of Formula I, wherein X=NHC(=0), n is 0, A is phenyl, optionally substituted with one or more A’, A’ is tert-butyl, F or oxo, R¹ is methyl and m=1.

The application provides a compound of Formula I, selected from the group consisting of:

6-tert-Butyl-8-fluoro-2-[4-(2-oxo-1,2-dihydro-pyridin-4-yl)-benzyl]-2H-phthalazin-1-one;

6-tert-Butyl-8-fluoro-2-[2-fluoro-4-(2-oxo-1,2-dihydro-pyridin-4-yl)-benzyl]-2H-phthalazin-1-one;

6-tert-Butyl-8-fluoro-2-[2-hydroxymethyl-3-(2-oxo-1,2-dihydro-pyridin-4-yl)-phenyl]-2H-phthalazin-1-one;

6-tert-Butyl-2-[2,6-difluoro-4-(2-oxo-1,2-dihydro-pyridin-4-yl)-benzyl]-8-fluoro-2H-phthalazin-1-one;

6-tert-Butyl-8-fluoro-2-[2-hydroxymethyl-4-(2-oxo-1,2-dihydro-pyridin-4-yl)-benzyl]-2H-phthalazin-1-one;

6-tert-Butyl-8-fluoro-2-[2-fluoro-4-[6-(1-methyl-1H-pyrazol-4-yl)-2-oxo-1,2-dihydro-pyridin-4-yl]-benzyl]-2H-phthalazin-1-one;

4-tert-Butyl-N-[2-methyl-3-(2-oxo-1,2-dihydro-pyridin-4-yl)-phenyl]-benzamide;

6-tert-Butyl-8-fluoro-2-[3-hydroxymethyl-4-(2-oxo-1,2-dihydro-pyridin-4-yl)-benzyl]-2H-phthalazin-1-one;

6-tert-Butyl-8-fluoro-2-[2-fluoro-5-hydroxymethyl-4-(2-oxo-1,2-dihydro-pyridin-4-yl)-benzyl]-2H-phthalazin-1-one; and

2-tert-Butyl-5-[2-fluoro-4-[6-(1-methyl-1H-pyrazol-4-yl)-2-oxo-1,2-dihydro-pyridin-4-yl]-benzyl]-4,5-dihydro-thieno[2,3-c]pyrrol-6-one.
The application provides a method for treating an inflammatory and/or autoimmune condition comprising administering to a patient in need thereof a therapeutically effective amount of the compound of Formula I.

The application provides a method for treating rheumatoid arthritis comprising administering to a patient in need thereof a therapeutically effective amount of the compound of Formula I.

The application provides a method for treating asthma comprising administering to a patient in need thereof a therapeutically effective amount of the compound of Formula I.

The application provides a pharmaceutical composition comprising the compound of Formula I.

The application provides a pharmaceutical composition comprising the compound of Formula I, admixed with at least one pharmaceutically acceptable carrier, excipient or diluent.

The application provides a use of the compound of formula I in the manufacture of a medicament for the treatment of an inflammatory disorder.

The application provides a use of the compound of formula I in the manufacture of a medicament for the treatment of an autoimmune disorder.

The application provides a use of the compound of formula I in the manufacture of a medicament for the treatment of rheumatoid arthritis.

The application provides a use of the compound of formula I in the manufacture of a medicament for the treatment of asthma.

The application provides the use of a compound as described above for the treatment of inflammatory and/or autoimmune condition.

The application provides the use of a compound as described above for the treatment of rheumatoid arthritis.

The application provides the use of a compound as described above for the treatment of asthma.

The application provides a compound, method, or composition as described herein.
Compounds and Preparation

Examples of representative compounds encompassed by the present invention and within the scope of the invention are provided in the following Table. These examples and preparations which follow are provided to enable those skilled in the art to more clearly understand and to practice the present invention. They should not be considered as limiting the scope of the invention, but merely as being illustrative and representative thereof.

In general, the nomenclature used in this Application is based on AUTONOMTM v.4.0, a Beilstein Institute computerized system for the generation of IUPAC systematic nomenclature. If there is a discrepancy between a depicted structure and a name given that structure, the depicted structure is to be accorded more weight. In addition, if the stereochemistry of a structure or a portion of a structure is not indicated with, for example, bold or dashed lines, the structure or portion of the structure is to be interpreted as encompassing all stereoisomers of it.
TABLE I depicts examples of compounds according to generic Formula I:

<table>
<thead>
<tr>
<th>Compound</th>
<th>Nomenclature</th>
<th>Structure</th>
</tr>
</thead>
<tbody>
<tr>
<td>I-1</td>
<td>6-tert-Butyl-8-fluoro-2-[4-(2-oxo-1,2-dihydropyridin-4-yl)-benzyl]-2H-phthalazin-1-one</td>
<td>![Image]</td>
</tr>
<tr>
<td>I-2</td>
<td>6-tert-Butyl-8-fluoro-2-[2-fluoro-4-(2-oxo-1,2-dihydropyridin-4-yl)-benzyl]-2H-phthalazin-1-one</td>
<td>![Image]</td>
</tr>
<tr>
<td>I-3</td>
<td>6-tert-Butyl-8-fluoro-2-[2-hydroxymethyl-3-(2-oxo-1,2-dihydro-pyridin-4-yl)-phenyl]-2H-phthalazin-1-one</td>
<td></td>
</tr>
<tr>
<td>-----</td>
<td>-----------------------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>I-4</td>
<td>6-tert-Butyl-2-[2,6-difluoro-4-(2-oxo-1,2-dihydro-pyridin-4-yl)-benzyl]-8-fluoro-2H-phthalazin-1-one</td>
<td></td>
</tr>
<tr>
<td>I-5</td>
<td>6-tert-Butyl-8-fluoro-2-[2-hydroxymethyl-4-(2-oxo-1,2-dihydro-pyridin-4-yl)-benzyl]-2H-phthalazin-1-one</td>
<td></td>
</tr>
<tr>
<td>I-6</td>
<td>6-tert-Butyl-8-fluoro-2-{2-fluoro-4-[6-(1-methyl-1H-pyrazol-4-yl)-2-oxo-1,2-dihydro-pyridin-4-yl]-benzyl}-2H-phthalazin-1-one</td>
<td></td>
</tr>
<tr>
<td>-----</td>
<td>------------------------------------------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>I-7</td>
<td>4-tert-Butyl-N-[2-methyl-3-(2-oxo-1,2-dihydro-pyridin-4-yl)-phenyl]-benzamide</td>
<td></td>
</tr>
<tr>
<td>I-8</td>
<td>6-tert-Butyl-8-fluoro-2-[3-hydroxymethyl-4-(2-oxo-1,2-dihydro-pyridin-4-yl)-benzyl]-2H-phthalazin-1-one</td>
<td></td>
</tr>
</tbody>
</table>
### General Synthetic Schemes

The compounds of the present invention may be prepared by any conventional means. Suitable processes for synthesizing these compounds are provided in the examples. Generally, compounds of the invention may be prepared according to the schemes below.
Compounds of formula 6, where R is as described above in the genus of formula I, may be prepared according to scheme 1. Starting with a compound of formula 1, where X is a leaving group such as bromide or chloride, and the phthalazinone derivative of formula 2 (which may be prepared as described in Berthel, S. et al. US 20100222325 Column 139), an alkylation reaction gives the bromobenzene derivative of formula 3. Palladium-catalyzed coupling with the boronic acid of formula 4 gives the biaryl of formula 5. Cleavage of the methoxy group then gives the compound of the invention of formula 6.

The alkylation of phthalazinone 2 may be carried out by treating the phthalazinone with a strong base such as sodium hydride and then treating the resulting anion with a benzyl halide derivative of formula 1. The reaction is conveniently carried out in an inert solvent such as dimethylformamide at a temperature about 70 °C for the generation of the anion, and at about room temperature for the alkylation reaction.

The cross-coupling reaction between bromobenzene derivative 3 and 2-methoxy-pyridine-4-boronic acid (4) to afford the biaryl intermediate 5 can be carried out in the presence of a palladium catalyst source such as or bis(dibenzylideneacetone)palladium(0) or tris(dibenzylideneacetone)dipalladium(0) and a phosphine ligand such as tricyclohexylphosphine.
Alternatively, tetrakis(triphenylphosphine)palladium(0) may be used as both the palladium catalyst and the phosphine ligand. The reaction is carried out in the presence of a base such as potassium acetate or sodium carbonate or potassium carbonate (Chemical Reviews 1995, 95, 2457-2483). The reaction can occur in an inert solvent such as DMF or aqueous dioxane or a mixture of dimethoxyethane and ethanol, using either conventional heating or microwave heating at temperatures between 90 °C and 150 °C for reaction times between one hour and several hours.

Several different reaction conditions may be employed for the cleavage of the methoxy group in the compound of formula 5. For example, the reaction may be conveniently effected by heating the methoxypyridine of formula 5 with trimethylsilyl chloride and sodium iodide in a solvent such as acetonitrile for several hours. Examples of specific conditions that can be used for this reaction may be found in the literature, for example in Litchfield, J. et al. Bioorg. Med. Chem. Lett. 2010, 20, 6262-6267; in Ando, M. et al. Bioorg. Med. Chem. 2009, 17, 6106-6122; or in Bigg, D. et al. US 20010000521. The reaction may also be effected by treating the methoxypyridine of formula 5 with trimethylsilyl iodide in chloroform or dichloromethane or acetonitrile at a temperature between about room temperature and about 50 °C as described in Van Eis, M. et al. WO 2008122614 page 35; in Leznoff, C. C. et al. J. Heterocycl. Chem. 1985, 22, 145-147; and in Hadida Ruah, S. WO 2008141119 page 143. The reaction may also be carried out by treating the compound of formula 5 with boron tribromide in dichloromethane at about 0 °C as described in Williams, T. M. et al. US 5,527,819 Example 76. The reaction may also be carried out by treating the compound of formula 5 with phosphorus tribromide in 1,2-dichloroethane at reflux, as described in Berdini, V. et al. 20100120761 Page 75; and in McElroy W. T. and DeShong, P. Tetrahedron 2006, 62, 6945-6954. Alternatively, the reaction may be carried out by treating the compound of formula 5 with 3M HCl or 10 M HCl at elevated temperatures such as at about 100 °C to 120 °C as described in Guzzo, P. et al. US 20090082359 Page 61; and in Cheng, D. et al. WO 2012003189 Page 98. As a further alternative, the reaction may be carried out by treating the compound of formula 5 with pyridine hydrochloride either neat or in a solvent such as DMF or in water at a temperature between about 100 °C and about 150 °C as described in Andrews, M. J. I et al. WO 2007138072 Page 108; or in Wallberg, A. et al. US 20070259860 Example 36. 1.
Compounds of the invention of formula 11 may be made as shown in Scheme 2. According to this process, the bromobenzene derivative of formula 3 undergoes a palladium-catalyzed coupling reaction with 2,6-dichloro-pyridine-4-boronic acid (7) to give the dichloropyridine derivative of formula 8. Compound 8 then undergoes a palladium-catalyzed coupling reaction with 1-methyl-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-pyrazole (9) to give the compound of formula 10. Cleavage of the methoxy group then gives the compound of the invention of formula 11.

The cross-coupling reaction between bromobenzene derivative 3 and 2,6-dichloro-pyridine-4-boronic acid (7) to afford the biaryl intermediate 8 can be carried out in the presence of a palladium catalyst source such as bis(dibenzylideneacetone)palladium(0) or tris(dibenzylideneacetone)dipalladium(0) and a phosphine ligand such as tricyclohexylphosphine. Alternatively, tetrakis(triphenylphosphine)palladium(0) may be used as both the palladium catalyst and the phosphine ligand. The reaction is carried out in the presence of a base such as potassium acetate or sodium carbonate or potassium carbonate (Chemical Reviews 1995, 95, 2457-2483). The reaction can occur in an inert solvent such as DMF or aqueous dioxane or a mixture of dimethoxyethane and ethanol, using either conventional heating or microwave
heating at temperatures between 90 °C and 150 °C for reaction times between one hour and several hours.

The cross-coupling reaction between dichloropyridine derivative 8 and 1-methyl-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-pyrazole (9) to afford intermediate 10 can be carried out using conditions analogous to those described for the preparation of intermediate 8. That is to say that the compound of formula 8 may be treated with 1-methyl-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-pyrazole (9) in the presence of a palladium catalyst source such as or bis(dibenzylideneacetone)palladium(0) or tris(dibenzylideneacetone)dipalladium(0) and a phosphine ligand such as tricyclohexylphosphine. Alternatively, tetrakis(triphenylphosphine)palladium(0) may be used as both the palladium catalyst and the phosphine ligand. The reaction is carried out in the presence of a base such as potassium acetate or sodium carbonate or potassium carbonate (Chemical Reviews 1995, 95, 2457-2483). The reaction can occur in an inert solvent such as DMF or aqueous dioxane or a mixture of dimethoxyethane and ethanol, using either conventional heating or microwave heating at temperatures between 90 °C and 150 °C for reaction times between one hour and several hours.

The cleavage of the methoxy group in the methoxypyridine derivative of formula 10 may be carried out using any conventional procedure such as those enumerated above for the cleavage of the methoxy group in the compound of formula 5. For example, the reaction may be conveniently carried out by treating the compound of formula 10 with 10 M HCl at elevated temperatures such as at about 100 °C to 120 °C.
The compound of the invention of formula 16 may be made as shown in Scheme 3. According to this process, the compound of formula 2 undergoes a nucleophilic substitution reaction with 2-bromo-6-fluorobenzaldehyde (12) to give the intermediate of formula 13. Reduction of the aldehyde gives alcohol 14. This undergoes palladium-catalyzed coupling with 2-methoxy-pyridine-4-boronic acid (4) to afford the biaryl intermediate 15. Cleavage of the methoxy group affords the compound of the invention of formula 16.

The reaction between the phthalazinone of formula 2 with the benzaldehyde derivative of formula 12 may be conveniently carried out by treating the phthalazinone with the fluorobenzaldehyde in the presence of a base such as cesium carbonate and in the additional presence of methoxytrimethylsilane in an inert solvent such as DMF at a temperature between about 50 °C and about 80 °C for several hours.

The reduction of the aldehyde of formula 13 to give the alcohol of formula 14 is a reaction that is well known in the field of organic chemistry and one for which many possible conditions exist. Examples of reagents that can be used for this transformation may be found in Larock, R. C. "Comprehensive Organic Transformations" John Wiley & Sons Inc. NY 1999, pp. 1075 et seq. For example, the reaction may be conveniently effected by treating the compound of formula 13 with...
sodium borohydride in an inert solvent such as an alcohol (such as methanol or ethanol or isopropanol) or a mixture of such an alcohol with a co-solvent such as dichloromethane at a temperature between about 0 °C and about room temperature.

The cross-coupling reaction between bromobenzene derivative 14 and 2-methoxy-pyridine-4-boronic acid (4) to afford the biaryl intermediate 15 can be carried out in the presence of a palladium catalyst source such as bis(dibenzylideneacetone)palladium(0) or tris(dibenzylideneacetone)dipalladium(0) and a phosphine ligand such as tricyclohexylphosphine. Alternatively, tetrakis(triphenylphosphine)palladium(0) may be used as both the palladium catalyst and the phosphine ligand. The reaction is carried out in the presence of a base such as potassium acetate or sodium carbonate or potassium carbonate (Chemical Reviews 1995, 95, 2457-2483). The reaction can occur in an inert solvent such as DMF or aqueous dioxane or a mixture of dimethoxyethane and ethanol, using either conventional heating or microwave heating at temperatures between 90 °C and 150 °C for reaction times between one hour and several hours.

Several different reaction conditions may be employed for the cleavage of the methoxy group in the compound of formula 15 as outlined above for the preparation of the compound of formula 6.
The compound of formula 22 may be prepared as shown in Scheme 4. According to this procedure, 4-bromo-2-methoxy-pyridine (17) undergoes a palladium-catalyzed cross coupling reaction with 2-methoxy-pyridine-4-boronic acid (4) and the nitro group in the resulting compound of formula 18 is reduced to give aniline 19. Acylation of the aniline with the carboxylic acid of formula 20 followed by cleavage of the methoxy group gives the compound of the invention of formula 22.

The cross-coupling reaction between 4-bromo-2-methoxy-pyridine (17) and 2-methoxy-pyridine-4-boronic acid (4) to afford the biaryl intermediate 18 can be carried out in the presence of a palladium catalyst source such as or bis(dibenzylideneacetone)palladium(0) or tris(dibenzylideneacetone)dipalladium(0) and a phosphine ligand such as tricyclohexylphosphine. Alternatively, tetrakis(triphenylphosphine)palladium(0) may be used as both the palladium catalyst and the phosphine ligand. The reaction is carried out in the presence of a base such as potassium acetate or sodium carbonate or potassium carbonate (Chemical Reviews 1995, 95, 2457-2483). The reaction can occur in an inert solvent such as DMF or aqueous dioxane or a mixture of dimethoxyethane and ethanol, using either conventional heating or microwave heating at temperatures between 90 °C and 150 °C for reaction times between one hour and several hours.

The reduction of the nitro group in the compound of formula 18 can be effected using a variety of procedures well known to one of average skill in the field of organic synthesis. Many of these procedures are outlined in Laroc, R. C. Comprehensive Organic Transformations John Wiley & Sons Inc. NY 1999, pp. 823 et seq. One convenient approach is to treat the compound of formula 18 with hydrogen gas in the presence of a noble metal catalyst such as palladium-on-carbon in a solvent such an alcohol (e.g., methanol or ethanol) at a pressure between about one atmosphere of hydrogen and about three atmospheres of hydrogen at about room temperature.

The coupling of 4-tert-butyl-benzoic acid (20) with the aniline derivative of formula 19 can be achieved using methods well known in the field of organic chemistry. Methods for effecting such a transformation have been reviewed in Han, S.-Y. and Kim, Y.-A. Tetrahedron 2004, 60, 2447-2467 and more recently in El-Faham, A. and Albercio, F. Chem. Rev. 2011, 111, 6557-6602. For example, the reaction may conveniently be carried out by treated the compound of formula 19 with the compound of formula 20 in the presence of one of a number of coupling agents, a catalyst such as 1-hydroxybenzotriazole or 1-hydroxy-7-azabenzotriazole and a base such as pyridine, diisopropylethylamine, N-methylmorpholine, or triethylamine in an inert solvent such
as a chlorinated hydrocarbon (e.g., dichloromethane) or N,N-dimethylformamide or N-methylpyrrolidinone, at a temperature between about 0 °C and about room temperature, preferably at about room temperature. Examples of the coupling agents that may be used include BOP (benzotriazol-1-yl-oxy-tris(dimethyl-amino)-phosphonium hexafluorophosphate); BOP-C1 (N,N'-bis(2-oxo-3-oxazolidinyl)-phosphinic chloride); DCC (N,N'-dicyclohexylcarbodiimide); DIC (N,N'-diisopropylcarbodiimide); EDC (I-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride); FDPP (pentafluorophenyl diphenyl phosphinate); HATU (0-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate); HBTU (O-(benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate); PyBOP (benzotriazol-1-yl-oxy-tri(pyrrolidino)-phosphonium hexafluorophosphate); PyBroP (bromotri(pyrrolidino)phosphonium hexafluorophosphate); and TSTU (2-succinimido-1,1,3,3-tetramethyluronium tetrafluoroborate).

Several different reaction conditions may be employed for the cleavage of the methoxy group in the compound of formula 21 as outlined above for the preparation of the compound of formula 6.
Compounds of interest of formula 34, where R1 is either fluorine or hydrogen, can be prepared according to scheme 5. Starting with carbamate 23, a palladium-catalyzed borylation reaction with bis(pinacolato)diboron 24 provides the boronate ester intermediate 25. A cross coupling reaction of 25 and 2,6-dichloro-4-iodo pyridine 7 affords the biaryl intermediate 26. Treatment of 26 with sodium methoxide provides the methoxy substituted intermediate 27. A cross coupling reaction of 27 and 1-methyl-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-pyrazole (9) generates intermediates of type 28. Removal of the boc protecting group in 28 to give amine 29 is followed by coupling with intermediate 30 to give ester 31. Hydrolysis of the
ester to give acid 32 followed by cyclization provides the final intermediate, lactam 33. Cleavage of the methyl ether then gives the compound of the invention of formula 34.

The palladium catalyzed borylation reaction of car bamates 23 can occur using bis(pinacolate)diboron 24, a suitable palladium catalyst source such as 1,1-bis(diphenylphosphino)ferrocene-palladium(II)dichloride, and potassium acetate (Journal of Organic Chemistry 1995, 60, 7508-7510). The reaction may proceed in an appropriate solvent such as dioxane, DMF, or NMP using either conventional heating or microwave heating at temperatures between 90 °C and 150 °C for reaction times between one hour and several hours.

The cross-coupling reaction between boronate ester 25 and 2,6-dichloro-4-iodo pyridine (7) to afford the biaryl intermediate 26 can be carried out in the presence of a palladium catalyst source such as tetrakis(triphenylphosphine)palladium(0) and a base such as potassium acetate (Chemical Reviews 1995, 95, 2457-2483). The reaction can occur in an inert solvent such as DMF using either conventional heating or microwave heating at temperatures between 90 °C and 150 °C for reaction times between one hour and several hours.

The conversion of intermediate 26 to the methyl ether 27 may occur in the presence of sodium methoxide in methanol. The reaction can proceed at 65 °C for several hours.

The cross-coupling reaction between intermediate 27 and 1-methyl-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-pyrazole (9) to afford intermediate 28 can be carried out in the presence of a palladium catalyst source such as tetrakis(triphenylphosphine)palladium(0) and a base such as potassium carbonate (Chemical Reviews 1995, 95, 2457-2483). The reaction can occur in an inert solvent such as DMF using either conventional heating or microwave heating at temperatures between 90 °C and 150 °C for reaction times between one hour and several hours.

Removal of the boc protecting group in 28 to afford the primary amine 29 can occur using an excess of an acid such as trifluoroacetic acid and an appropriate solvent such as dichloromethane. The reaction can proceed at room temperature for reaction times ranging between several minutes and several hours.

The condensation reaction between the amine intermediate 29 and carboxylic acid 30 may occur in the presence of an appropriate amide coupling reagent such as HATU using an amine base such as triethylamine or Hunig's base (Chemical Reviews 2011, 111, 6557-6602). The reaction can occur in an inert solvent such as dichloromethane or DMF at room temperature for reaction
time between one hour and several hours. Note that carboxylic acid 30 may be made by
following the procedures described in Wang, X. et al. WO 2012030990 pages 52-53.

The hydrolysis of the ester in the compound of formula 31 may be conveniently carried out by
treating the ester with an alkali metal hydroxide such as sodium hydroxide or lithium hydroxide
in an inert solvent such as aqueous THF or a mixture of THF, methanol and water at a
temperature between about 0 °C and about 60 °C.

The cyclization of the amino acid of formula 32 to give the lactam of formula 33 is conveniently
effectected by treating the amino acid of formula 32 with a coupling agent such as PYBOP or
HBTU or EDC in an inert solvent such as DMF in the presence of a base such as triethylamine,
diisopropylethylamine, N-methylmorpholine, or pyridine at about room temperature for several
hours.

Several different reaction conditions may be employed for the cleavage of the methoxy group in
the compound of formula 33, as outlined above for the preparation of the compound of formula 6.
For example, the compound of formula 33 may be treated with trimethylsilyl chloride and
sodium iodide in a solvent such as acetonitrile about 80 °C for several hours to provide the
compound of interest of formula 34.

**Scheme 6**

![Scheme 6](image)

Many benzyl bromides and benzyl chlorides of formula 1 are commercially available. Many
others are known and may be prepared using procedures that have been disclosed in the literature,
or are described in the examples below. Still others may be prepared using procedures that have
been disclosed in the literature for the preparation of other compounds of this class, for example
using the procedure depicted in Scheme 6.
For example, compounds of formula \( \mathbf{1} \) where \( X \) represents bromine can be prepared by treating a compound of formula \( \mathbf{35} \) where \( Y \) represents hydrogen with \( \text{N-bromosuccinimide} \) or 3,3-dimethyl-N,N'-dibromohydantoin in an inert solvent such as a halogenated alkane (for example, carbon tetrachloride) or acetonitrile, in the optional addition presence of a catalyst such as azobis(isobutyronitrile) or benzyol peroxide at a suitable temperature, conveniently at the boiling point of the solvent, and in the optional additional presence of a source of light; or by treating a compound of formula \( \mathbf{35} \) where \( Y \) represents hydrogen with bromine in an inert solvent such as a mixture of water and an aromatic hydrocarbon (e.g., benzene) or a halogenated alkane (e.g., chloroform) under irradiation with an incandescent light. Compounds of formula \( \mathbf{1} \) where \( X \) represents chlorine can be prepared by treating a compound of formula \( \mathbf{35} \) where \( Y \) represents hydrogen with \( \text{N-chlorosuccinimide} \) or sulfuryl chloride in an inert solvent such as a halogenated alkane (for example, carbon tetrachloride) or acetonitrile in the optional additional presence of a catalyst such as azobis(isobutyronitrile) or benzyol peroxide at a suitable temperature, conveniently at the boiling point of the solvent, and in the optional additional presence of a source of light; or by treating a compound of formula \( \mathbf{35} \) where \( Y \) represents hydrogen with chlorine in an inert solvent such as a mixture of water and an aromatic hydrocarbon (e.g., benzene) or a halogenated alkane (e.g., chloroform or carbon tetrachloride) under irradiation with an incandescent light.

A compound of formula \( \mathbf{1} \) where \( X \) represents bromine can be prepared by treating a compound of formula \( \mathbf{35} \) where \( Y \) represents \( \text{OH} \) with phosphorus tribromide or a mixture of \( \text{N-bromosuccinimide} \) and triphenylphosphine in an inert solvent such as a halogenated alkane (e.g., methylene chloride or carbon tetrachloride) at a temperature between about 0 degrees and the boiling point of the solvent, conveniently at about 0 degrees. A compound of formula \( \mathbf{1} \) where \( X \) represents chlorine can be prepared by treating a compound of formula \( \mathbf{35} \) where \( Y \) represents \( \text{OH} \) with thionyl chloride or a mixture of \( \text{N-chlorosuccinimide} \) and triphenylphosphine in an inert solvent such as a halogenated alkane (e.g., methylene chloride or carbon tetrachloride) at a temperature between about 0 degrees and the boiling point of the solvent, conveniently at about 0 degrees.
Compounds of formula 1 where R1 represents a hydroxymethyl group (for example, compounds of formula 38) may also be conveniently prepared from the corresponding carboxylic acid or carboxylate ester, which in some cases are more readily available commercially than the alcohols. Scheme 6 shows a process which may be used to prepare intermediates of formula 38 from carboxylic acids of formula 36 where R2 represents hydrogen or carboxylate esters of formula 36 where R2 represents lower alkyl, for example methyl. According to the process outlined in Scheme 6, the starting material of formula 36 is brominated to give the intermediate of formula 37, and the latter is then reduced to give the intermediate of formula 38.

The compound of formula 36 is conveniently converted to the bromomethyl derivative of formula 37 using one of the conditions outlined above for the conversion of a compound of formula 35 to a compound of formula 1 where X represents bromide. For example, the compound of formula 36 may be treated with N-bromosuccinimide in the presence of azobis(isobutyro)nitrile or benzoyl peroxide in a solvent such as acetonitrile or carbon tetrachloride at the reflux temperature of the solvent for several hours.

An intermediate of formula 37 where R2 represents hydrogen may be converted to the hydroxymethyl derivative of formula 38 by treating it with a reducing agent such as borane-methyl sulfide complex in tetrahydrofuran at about 0 °C for several hours. An intermediate of formula 37 where R2 represents lower alkyl such as methyl may be converted to the hydroxymethyl derivative of formula 38 by treating it with a reducing agent such as diisobutylaluminum hydride in a solvent such as toluene at about 0 °C for several hours.
Pharmaceutical Compositions and Administration

The compounds of the present invention may be formulated in a wide variety of oral administration dosage forms and carriers. Oral administration can be in the form of tablets, coated tablets, dragees, hard and soft gelatin capsules, solutions, emulsions, syrups, or suspensions. Compounds of the present invention are efficacious when administered by other routes of administration including continuous (intravenous drip) topical parenteral, intramuscular, intravenous, subcutaneous, transdermal (which may include a penetration enhancement agent), buccal, nasal, inhalation and suppository administration, among other routes of administration. The preferred manner of administration is generally oral using a convenient daily dosing regimen which can be adjusted according to the degree of affliction and the patient's response to the active ingredient.

A compound or compounds of the present invention, as well as their pharmaceutically useable salts, together with one or more conventional excipients, carriers, or diluents, may be placed into the form of pharmaceutical compositions and unit dosages. The pharmaceutical compositions and unit dosage forms may be comprised of conventional ingredients in conventional proportions, with or without additional active compounds or principles, and the unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed. The pharmaceutical compositions may be employed as solids, such as tablets or filled capsules, semisolids, powders, sustained release formulations, or liquids such as solutions, suspensions, emulsions, elixirs, or filled capsules for oral use; or in the form of suppositories for rectal or vaginal administration; or in the form of sterile injectable solutions for parenteral use. A typical preparation will contain from about 5% to about 95% active compound or compounds (w/w). The term "preparation" or "dosage form" is intended to include both solid and liquid formulations of the active compound and one skilled in the art will appreciate that an active ingredient can exist in different preparations depending on the target organ or tissue and on the desired dose and pharmacokinetic parameters.

The term "excipient" as used herein refers to a compound that is useful in preparing a pharmaceutical composition, generally safe, non-toxic and neither biologically nor otherwise undesirable, and includes excipients that are acceptable for veterinary use as well as human pharmaceutical use. The compounds of this invention can be administered alone but will generally be administered in admixture with one or more suitable pharmaceutical excipients,
diluents or carriers selected with regard to the intended route of administration and standard pharmaceutical practice.

"Pharmaceutically acceptable" means that which is useful in preparing a pharmaceutical composition that is generally safe, non-toxic, and neither biologically nor otherwise undesirable and includes that which is acceptable for veterinary as well as human pharmaceutical use.

A "pharmaceutically acceptable salt" form of an active ingredient may also initially confer a desirable pharmacokinetic property on the active ingredient which were absent in the non-salt form, and may even positively affect the pharmacodynamics of the active ingredient with respect to its therapeutic activity in the body. The phrase "pharmaceutically acceptable salt" of a compound means a salt that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound. Such salts include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2.2.2]oct-2-ene-1-carboxylic acid, glucoheptonic acid, 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, and the like; or (2) salts formed when an acidic proton present in the parent compound either is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base such as ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, and the like.

Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier may be one or more substances which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material. In powders, the carrier generally is a finely divided solid which is a mixture with the finely divided active component. In tablets, the active component generally is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted in the shape and size desired. Suitable carriers include but
are not limited to magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. Solid form preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.

Liquid formulations also are suitable for oral administration include liquid formulation including emulsions, syrups, elixirs, aqueous solutions, aqueous suspensions. These include solid form preparations which are intended to be converted to liquid form preparations shortly before use. Emulsions may be prepared in solutions, for example, in aqueous propylene glycol solutions or may contain emulsifying agents such as lecithin, sorbitan monooleate, or acacia. Aqueous solutions can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizing, and thickening agents. Aqueous suspensions can be prepared by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well known suspending agents.

The compounds of the present invention may be formulated for parenteral administration (e.g., by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in ampoules, pre-filled syringes, small volume infusion or in multi-dose containers with an added preservative. The compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, for example solutions in aqueous polyethylene glycol. Examples of oily or nonaqueous carriers, diluents, solvents or vehicles include propylene glycol, polyethylene glycol, vegetable oils (e.g., olive oil), and injectable organic esters (e.g., ethyl oleate), and may contain formulatory agents such as preserving, wetting, emulsifying or suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilization from solution for constitution before use with a suitable vehicle, e.g., sterile, pyrogen-free water.

The compounds of the present invention may be formulated for topical administration to the epidermis as ointments, creams or lotions, or as a transdermal patch. Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents. Lotions may be formulated with an aqueous or oily base and will in general also containing one or more emulsifying agents, stabilizing agents, dispersing agents, suspending agents, thickening agents, or coloring agents. Formulations suitable for
Topical administration in the mouth include lozenges comprising active agents in a flavored base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatin and glycerin or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.

The compounds of the present invention may be formulated for administration as suppositories. A low melting wax, such as a mixture of fatty acid glycerides or cocoa butter is first melted and the active component is dispersed homogeneously, for example, by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool, and to solidify.

The compounds of the present invention may be formulated for vaginal administration. Pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate.

The compounds of the present invention may be formulated for nasal administration. The solutions or suspensions are applied directly to the nasal cavity by conventional means, for example, with a dropper, pipette or spray. The formulations may be provided in a single or multidose form. In the latter case of a dropper or pipette, this may be achieved by the patient administering an appropriate, predetermined volume of the solution or suspension. In the case of a spray, this may be achieved for example by means of a metering atomizing spray pump.

The compounds of the present invention may be formulated for aerosol administration, particularly to the respiratory tract and including intranasal administration. The compound will generally have a small particle size for example of the order of five (5) microns or less. Such a particle size may be obtained by means known in the art, for example by micronization. The active ingredient is provided in a pressurized pack with a suitable propellant such as a chlorofluorocarbon (CFC), for example, dichlorodifluoromethane, trichlorofluoromethane, or dichlorotetrafluoroethane, or carbon dioxide or other suitable gas. The aerosol may conveniently also contain a surfactant such as lecithin. The dose of drug may be controlled by a metered valve. Alternatively the active ingredients may be provided in a form of a dry powder, for example a powder mix of the compound in a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidone (PVP). The powder carrier will form a gel in the nasal cavity. The powder composition may be presented in unit
dose form for example in capsules or cartridges of e.g., gelatin or blister packs from which the powder may be administered by means of an inhaler.

When desired, formulations can be prepared with enteric coatings adapted for sustained or controlled release administration of the active ingredient. For example, the compounds of the present invention can be formulated in transdermal or subcutaneous drug delivery devices. These delivery systems are advantageous when sustained release of the compound is necessary and when patient compliance with a treatment regimen is crucial. Compounds in transdermal delivery systems are frequently attached to a skin-adhesive solid support. The compound of interest can also be combined with a penetration enhancer, e.g., Azone (1-dodecylazacycloheptan-2-one). Sustained release delivery systems are inserted subcutaneously into the subdermal layer by surgery or injection. The subdermal implants encapsulate the compound in a lipid soluble membrane, e.g., silicone rubber, or a biodegradable polymer, e.g., polyactic acid.

Suitable formulations along with pharmaceutical carriers, diluents and excipients are described in *Remington: The Science and Practice of Pharmacy* 1995, edited by E. W. Martin, Mack Publishing Company, 19th edition, Easton, Pennsylvania. A skilled formulation scientist may modify the formulations within the teachings of the specification to provide numerous formulations for a particular route of administration without rendering the compositions of the present invention unstable or compromising their therapeutic activity.

The modification of the present compounds to render them more soluble in water or other vehicle, for example, may be easily accomplished by minor modifications (salt formulation, esterification, etc.), which are well within the ordinary skill in the art. It is also well within the ordinary skill of the art to modify the route of administration and dosage regimen of a particular compound in order to manage the pharmacokinetics of the present compounds for maximum beneficial effect in patients.

The term "therapeutically effective amount" as used herein means an amount required to reduce symptoms of the disease in an individual. The dose will be adjusted to the individual requirements in each particular case. That dosage can vary within wide limits depending upon numerous factors such as the severity of the disease to be treated, the age and general health condition of the patient, other medicaments with which the patient is being treated, the route and form of administration and the preferences and experience of the medical practitioner involved. For oral administration, a daily dosage of between about 0.01 and about 1000 mg/kg body
weight per day should be appropriate in monotherapy and/or in combination therapy. A preferred
daily dosage is between about 0.1 and about 500 mg/kg body weight, more preferred 0.1 and
about 100 mg/kg body weight and most preferred 1.0 and about 10 mg/kg body weight per day.
Thus, for administration to a 70 kg person, the dosage range would be about 7 mg to 0.7 g per
day. The daily dosage can be administered as a single dosage or in divided dosages, typically
between 1 and 5 dosages per day. Generally, treatment is initiated with smaller dosages which
are less than the optimum dose of the compound. Thereafter, the dosage is increased by small
increments until the optimum effect for the individual patient is reached. One of ordinary skill in
treating diseases described herein will be able, without undue experimentation and in reliance on
personal knowledge, experience and the disclosures of this application, to ascertain a
therapeutically effective amount of the compounds of the present invention for a given disease
and patient.

The pharmaceutical preparations are preferably in unit dosage forms. In such form, the
preparation is subdivided into unit doses containing appropriate quantities of the active
component. The unit dosage form can be a packaged preparation, the package containing
discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or
ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can
be the appropriate number of any of these in packaged form.

**Indications and Methods of Treatment**

The compounds of generic Formula I inhibit Bruton's tyrosine kinase (Btk). Activation of Btk
by upstream kinases results in activation of phospholipase-Cy which, in turn, stimulates release
of pro-inflammatory mediators. Compounds of Formula I are useful in the treatment of arthritis
and other anti-inflammatory and auto-immune diseases. Compounds according to Formula I are,
accordingly, useful for the treatment of arthritis. Compounds of Formula I are useful for
inhibiting Btk in cells and for modulating B-cell development. The present invention further
comprises pharmaceutical compositions containing compounds of Formula I admixed with
pharmacologically acceptable carrier, excipients or diluents.

The compounds described herein are kinase inhibitors, in particular Btk inhibitors. These
inhibitors can be useful for treating one or more diseases responsive to kinase inhibition,
including diseases responsive to Btk inhibition and/or inhibition of B-cell proliferation, in
mammals. Without wishing to be bound to any particular theory, it is believed that the
interaction of the compounds of the invention with Btk results in the inhibition of Btk activity and thus in the pharmaceutical utility of these compounds. Accordingly, the invention includes a method of treating a mammal, for instance a human, having a disease responsive to inhibition of Btk activity, and/or inhibiting B-cell proliferation, comprising administrating to the mammal having such a disease, an effective amount of at least one chemical entity provided herein. An effective concentration may be ascertained experimentally, for example by assaying blood concentration of the compound, or theoretically, by calculating bioavailability. Other kinases that may be affected in addition to Btk include, but are not limited to, other tyrosine kinases and serine/threonine kinases.

Kinases play notable roles in signaling pathways controlling fundamental cellular processes such as proliferation, differentiation, and death (apoptosis). Abnormal kinase activity has been implicated in a wide range of diseases, including multiple cancers, autoimmune and/or inflammatory diseases, and acute inflammatory reactions. The multifaceted role of kinases in key cell signaling pathways provides a significant opportunity to identify novel drugs targeting kinases and signaling pathways.

An embodiment includes a method of treating a patient having an autoimmune and/or inflammatory disease, or an acute inflammatory reaction responsive to inhibition of Btk activity and/or B-cell proliferation.

Autoimmune and/or inflammatory diseases that can be affected using compounds and compositions according to the invention include, but are not limited to: psoriasis, allergy, Crohn's disease, irritable bowel syndrome, Sjogren's disease, tissue graft rejection, and hyperacute rejection of transplanted organs, asthma, systemic lupus erythematosus (and associated glomerulonephritis), dermatomyositis, multiple sclerosis, scleroderma, vasculitis (ANCA-associated and other vasculitides), autoimmune hemolytic and thrombocytopenic states, Goodpasture's syndrome (and associated glomerulonephritis and pulmonary hemorrhage), atherosclerosis, rheumatoid arthritis, chronic Idiopathic thrombocytopenic purpura (ITP), Addison's disease, Parkinson's disease, Alzheimer's disease, diabetes, septic shock, and myasthenia gravis.

Included herein are methods of treatment in which at least one chemical entity provided herein is administered in combination with an anti-inflammatory agent. Anti-inflammatory agents include but are not limited to NSAIDs, non-specific and COX-2 specific cyclooxygenase enzyme
inhibitors, gold compounds, corticosteroids, methotrexate, tumor necrosis factor receptor (TNF) receptors antagonists, immunosuppressants and methotrexate.

Examples of NSAIDs include, but are not limited to, ibuprofen, flurbiprofen, naproxen and naproxen sodium, diclofenac, combinations of diclofenac sodium and misoprostol, sulindac, oxaprozin, diflunisal, piroxicam, indomethacin, etodolac, fenoprofen calcium, ketoprofen, sodium nabumetone, sulfasalazine, tolmé tin sodium, and hydroxychloroquine. Examples of NSAIDs also include COX-2 specific inhibitors such as celecoxib, valdecoxib, lumiracoxib and/or etoricoxib.

In some embodiments, the anti-inflammatory agent is a salicylate. Salicylates include by are not limited to acetylsalicylic acid or aspirin, sodium salicylate, and choline and magnesium salicylates.

The anti-inflammatory agent may also be a corticosteroid. For example, the corticosteroid may be cortisone, dexamethasone, methylprednisolone, prednisolone, prednisolone sodium phosphate, or prednisone.

In additional embodiments the anti-inflammatory agent is a gold compound such as gold sodium thiomalate or auranofin.

The invention also includes embodiments in which the anti-inflammatory agent is a metabolic inhibitor such as a dihydrofolate reductase inhibitor, such as methotrexate or a dihydroorotate dehydrogenase inhibitor, such as leflunomide.

Other embodiments of the invention pertain to combinations in which at least one anti-inflammatory compound is an anti-C5 monoclonal antibody (such as eculizumab or pexelizumab), a TNF antagonist, such as entanercept, or infliximab, which is an anti-TNF alpha monoclonal antibody.

Still other embodiments of the invention pertain to combinations in which at least one active agent is an immunosuppressant compound such as an immunosuppressant compound chosen from methotrexate, leflunomide, cyclosporine, tacrolimus, azathioprine, and mycophenolate mofetil.

B-cells and B-cell precursors expressing BTK have been implicated in the pathology of B-cell malignancies, including, but not limited to, B-cell lymphoma, lymphoma (including Hodgkin's
and non-Hodgkin's lymphoma), hairy cell lymphoma, multiple myeloma, chronic and acute myelogenous leukemia and chronic and acute lymphocytic leukemia.

BTK has been shown to be an inhibitor of the Fas/APO-1 (CD-95) death inducing signaling complex (DISC) in B-lineage lymphoid cells. The fate of leukemia/lymphoma cells may reside in the balance between the opposing proapoptotic effects of caspases activated by DISC and an upstream anti-apoptotic regulatory mechanism involving BTK and/or its substrates (Vassilev et al, J. Biol. Chem. 1998, 274, 1646-1656).

It has also been discovered that BTK inhibitors are useful as chemosensitizing agents, and, thus, are useful in combination with other chemotherapeutic drugs, in particular, drugs that induce apoptosis. Examples of other chemotherapeutic drugs that can be used in combination with chemosensitizing BTK inhibitors include topoisomerase I inhibitors (camptothecin or topotecan), topoisomerase II inhibitors (e.g. daunomycin and etoposide), alkylating agents (e.g. cyclophosphamide, melphalan and BCNU), tubulin directed agents (e.g. taxol and vinblastine), and biological agents (e.g. antibodies such as anti CD20 antibody, IDEC 8, immunotoxins, and cytokines).

Btk activity has also been associated with some leukemias expressing the bcr-abl fusion gene resulting from translocation of parts of chromosome 9 and 22. This abnormality is commonly observed in chronic myelogenous leukemia. Btk is constitutively phosphorylated by the bcr-abl kinase which initiates downstream survival signals which circumvents apoptosis in bcr-abl cells. (N. Feldhahn et al. J. Exp. Med. 2005 201(11):1837-1852).

Methods of Treatment

The application provides a method for treating an inflammatory and/or autoimmune condition comprising administering to a patient in need thereof a therapeutically effective amount of the compound of Formula I.

The application provides a method for treating an inflammatory condition comprising administering to a patient in need thereof a therapeutically effective amount of the compound of Formula I.

The application provides a method for treating rheumatoid arthritis comprising administering to a patient in need thereof a therapeutically effective amount of the compound of Formula I.
The application provides a method for treating asthma comprising administering to a patient in need thereof a therapeutically effective amount of Formula I.

The application provides a method for treating an inflammatory and/or autoimmune condition comprising administering to a patient in need thereof a therapeutically effective amount of the Btk inhibitor compound of Formulae I.

The application provides a method for treating arthritis comprising administering to a patient in need thereof a therapeutically effective amount of the Btk inhibitor compound of Formula I.

The application provides a method for treating asthma comprising administering to a patient in need thereof a therapeutically effective amount of the Btk inhibitor compound of Formula I.

The application provides a method of inhibiting B-cell proliferation comprising administering to a patient in need thereof a therapeutically effective amount of the Btk inhibitor compound of Formula I.

The application provides a method for inhibiting Btk activity comprising administering the Btk inhibitor compound of any one of Formula I, wherein the Btk inhibitor compound exhibits an IC$_{50}$ of 50 micromolar or less in an in vitro biochemical assay of Btk activity.

In one variation of the above method, the Btk inhibitor compound exhibits an IC$_{50}$ of 100 nanomolar or less in an in vitro biochemical assay of Btk activity.

In another variation of the above method, the compound exhibits an IC$_{50}$ of 10 nanomolar or less in an in vitro biochemical assay of Btk activity.

The application provides a method for treating an inflammatory condition comprising co-administering to a patient in need thereof a therapeutically effective amount of an anti-inflammatory compound in combination with the Btk inhibitor compound of Formula I.

The application provides a method for treating arthritis comprising co-administering to a patient in need thereof a therapeutically effective amount of an anti-inflammatory compound in combination with the Btk inhibitor compound of Formula I.

The application provides a method for treating a lymphoma or a BCR-ABL1 + leukemia cells by administering to a patient in need thereof a therapeutically effective amount of the Btk inhibitor compound of Formula I.
The application provides a use of the compound as described above for use as therapeutically active substance.

The application provides the use of the compound as described above for the preparation of a medicament for the treatment of an inflammatory and/or autoimmune condition.

The application provides the compound as described above for the treatment of an inflammatory and/or autoimmune condition.

The application provides the compound as described above for use in the treatment of an inflammatory and/or autoimmune condition.

The application provides the invention as hereinbefore described.

**EXAMPLES**

**General Abbreviations**

Commonly used abbreviations include: acetyl (Ac), azo-£z’s-isobutyrylnitrile (AIBN), atmospheres (Atm), 9-borabicyclo[3.3.1]nonane (9-BBN or BBN), 2, 2'-bis (diphenylphosphino)-l, 1', 1'-binaphthyl (BINAP), tert-butoxycarbonyl (Boc), di-tert-butyl pyrocarbonate or boc anhydride (BOC₂O), benzyl (Bn), butyl (Bu), Chemical Abstracts Registration Number (CASRN), benzoxycarbonyl (CBZ or Z), carbonyl diimidazole (CDI), 1, 4-diazabicyclo[2.2.2]octane (DABCO), diethylamino sulfur trifluoride (DAST), dibenzylideneacetone (dba), 1, 5-diazabicyclo[4.3.0]non-5-ene (DBN), 1, 8-diazabicyclo[5.4.0]undec-7-ene (DBU), N,N'-dicyclohexylcarbodiimide (DCC), 1, 2-dichloro ethane (DCE), dichloromethane (DCM), 2, 3-Dichloro-5, 6-dicyano-1, 4-benzoquinone (DDQ), diethyl azodicarboxylate (DEAD), di-£so-propylazodicarboxylate (DIAD), di-iso-butylaluminumhydride (DIBAL or DIBAL-H), di-iso-propylethylene (DIPEA), N, N-dimethyl acetamide (DMA), 4-N, N-dimethylaminopyridine (DMAP), N,N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), 1, V-bis-(diphenylphosphino)ethane (dppe), 1, Y-bis-(diphenylphosphino)ferrocene (dpf), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI), 2-ethoxy-1-ethoxyacarbonyl-1, 2-dihydroquinoline (EEDQ), ethyl (Et), ethyl acetate (EtOAc), ethanol (EtOH), 2-ethoxy-2 H-quinoline-1-carboxylic acid ethyl ester (EEDQ), diethyl ether (Et₂O), ethyl isopropyl ether (EtOiPr), O- (7-azabenzotriazole-1-yl)-N, N, NN'-tetramethyluronium hexafluorophosphate acetic acid (HATU), acetic acid (HOAc), 1-N-
hydroxybenzotriazole (HOBt), high pressure liquid chromatography (HPLC), \( \alpha \)-propanol (IPA), isopropylmagnesium chloride (iPr mgCl), hexamethyl disilazane (HMDS), liquid chromatography mass spectrometry (LCMS), lithium hexamethyl disilazane (LiHMDS), meta-chloroperoxybenzoic acid (m-CPBA), methanol (MeOH), melting point (mp), MeSO\(_2^–\) (mesyl or Ms), methyl (Me), acetonitrile (MeCN), m-chloroperoxybenzoic acid (MCPBA), mass spectrum (ms), methyl t-butyl ether (MTBE), methyl tetrahydrofuran (MeTHF), N-bromosuccinimide (NBS), n-Butyllithium (nBuLi), N-carboxyanhydride (NCA), N-chlorosuccinimide (NCS), N-methylmorpholine (NMM), N-methylpyrrolidone (NMP), pyridinium chlorochromate (PCC), Dichloro- (bis-diphenylphosphino)ferrocenyl palladium (II) (Pd(dppf)Cl\(_2\)), palladium (II) acetate (Pd(OAc)\(_2\)), tris(dibenzylideneacetone)dipalladium (0) (Pd\(_2\)(dba)\(_3\)), pyridinium dichromate (PDC), phenyl (Ph), propyl (Pr), \( \alpha \)-propyl (z-Pr), pounds per square inch (psi), pyridine (pyr), 1, 2, 3, 4, 5-Pentaphenyl-L\(-\) (di-tert-butylphosphino)ferrocene (Q-Phos), room temperature (ambient temperature, rt or RT), sec-Butyllithium (sBuLi), tert-butyldimethylsilyl or t-BuMe\(_2\)Si (TBDMS), tetra-n-butylammonium fluoride (TBAF), triethylamine (TEA or Et\(_3\)N), 2, 2, 6, 6-tetramethylpiperidine 1-oxyl (TEMPO), trimethylsilylthoxymethyl (SEM), triflate or CF\(_3\)SO\(_2^–\) (Tf), trifluoro acetic acid (TFA), 1, V-bis-2, 2, 6, 6-tetramethylheptane-2, 6-dione (TMHD), O-benzotriazol-1-yl-N, N’, N’-tetramethyluronium tetrafluoroborate (TBTU), thin layer chromatography (TLC), tetrahydrofuran (THF), trimethylsilyl or Me\(_3\)Si (TMS), p-toluenesulfonic acid monohydrate (TsOH or pTsOH), 4-Me-C\(_6\)H\(_4\)SO\(_2^–\) or tosyl (Ts), N-urethane-N-carboxyanhydride (UNCA). Conventional nomenclature including the prefixes normal (n), iso (i-), secondary (sec-), tertiary (tert-) and neo have their customary meaning when used with an alkyl moiety. (J. Rigaudy and D. P. Klesney, Nomenclature in Organic Chemistry, IUPAC 1979 Pergamon Press, Oxford.).

General Conditions

Compounds of the present invention can be prepared beginning with the commercially available starting materials by utilizing general synthetic techniques and procedures known to those skilled in the art. Outlines below are reaction schemes suitable for preparing such compounds. Further exemplification can be found in the specific examples.
Preparative Examples

Specific Abbreviations

AIBN         Azobisisobutyronitrile
AlCl₃        Aluminum trichloride
5 BBr₃       Boron tribromide
BH₃-DMS      Borane-dimethyl sulfide complex.
CCl₄        Carbon tetrachloride
CH₂Cl₂      Dichloromethane
CH₃CN       Acetonitrile
10 Cs₂CO₃    Cesium carbonate
DIPEA       Diisopropylethylamine
DME         Dimethoxyethane
DMF         N,N-Dimethylformamide
EtOAc       Ethyl acetate
15 EtOH       Ethanol
HATU        0-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate
K₂CO₃       Potassium carbonate
KH₂PO₄      Potassium dihydrogen phosphate
KOAc        Potassium acetate
20 MeOH      Methanol
Na₂CO₃      Sodium carbonate
Na₂S₂O₃ Sodium thiosulfate
Na₂SO₄ Sodium sulfate
NaBH₄ Sodium borohydride
NaH Sodium hydride
5 NaHCO₃ Sodium hydrogen carbonate
Nal Sodium iodide
NaOMe Sodium methoxide
NH₄OAc Ammonium acetate
PBr₃ Phosphorus tribromide
10 Pd(dba)₂ Bis(dibenzylideneacetone)palladium(0)
Pd₂(dba)₃ Tris(dibenzylideneacetone)dipalladium(0)
Pd(OAc)₂ Palladium(II) acetate
Pd(PPh₃)₄ Tetrakis(triphenylphosphine)palladium(0)
iPrOH Isopropanol
15 PYBOP (Benzotriazol-1-yl-oxytrityrrolidinophosphonium hexafluorophosphate)
THF Tetrahydrofuran
X-Phos 2-Dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl

General Experimental Details

Reagents were purchased from Aldrich, Oakwood, Matrix or other suppliers and used without further purification. Reactions using microwave irradiation for heating were conducted using either a Personal Chemistry Emrys Optimizer System or a CEM Discovery System. The purification of multi-milligram to multi-gram scale was conducted by methods known to those skilled in the art such as elution of silica gel flash column; preparative flash column
purifications were also effected in some cases by use of disposal pre-packed multigram silica gel columns (RediSep) eluted with a CombiFlash system. Biotage™ and ISCO™ are also flash column instruments that may have been used in this invention for purification of intermediates.

For the purpose of judging compound identity and purity, LC/MS (liquid chromatography/mass spectroscopy) spectra were recorded using the following system. For measurement of mass spectra, the system consists of a Micromass Platform II spectrometer: ES Ionization in positive mode (mass range: 150 -1200). The simultaneous chromatographic separation was achieved with the following HPLC system: ES Industries Chromegabond WR C-18 3u 120A (3.2 x 30mm) column cartridge; Mobile Phase A: Water (0.02% TFA) and Phase B: Acetonitrile (0.02% TFA); gradient 10% B to 90% B in 3 minutes; equilibration time of 1 minute; flow rate of 2 mL/minute.

Many compounds of Formula 1 were also purified by reversed phased HPLC, using methods well known to those skilled in the art. In some cases, preparative HPLC purification was conducted using PE Sciex 150 EX Mass Spec controlling a Gilson 215 collector attached to a Shimadzu preparative HPLC system and a Leap autoinjector. Compounds were collected from the elution stream using LC/MS detection in the positive ion detection: The elution of compounds from C-18 columns (2.0 X 10 cm eluting at 20 mL/min) was effected using appropriate linear gradation mode over 10 minutes of Solvent (A) 0.05% TFA/H₂O and Solvent (B) 0.035% TFA/acetonitrile. For injection on to HPLC systems, the crude samples were dissolved in mixtures of methanol, acetonitrile and DMSO.

³H-NMR characterization was performed using Bruker or Varian 300 or 400 MHz NMR Spectrometers.

The compounds of the present invention may be synthesized according to known techniques. The following examples and references are provided to aid the understanding of the present invention. The examples are not intended, however, to limit the invention, the true scope of which is set forth in the appended claims. The names of the final products in the examples were generated using Isis AutoNom 2000.
Preparation of Intermediates

2-Fluoro-4-[2-methoxy-6-(1-methyl-1H-pyrazol-4-yl)-pyridin-4-yl]-benzylamine

Step 1: [2-Fluoro-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzyl]-carbamic acid tert-butyl ester

In a pressure tube, tert-butyl 4-bromo-2-fluorobenzyl carbamate (5 g, 16.4 mmol), bis(pinacolato)diboron (6.26 g, 24.7 mmol) and potassium acetate (4.84 g, 49.3 mmol) were combined with NMP (75.0 mL) to give a light yellow solution. The reaction mixture was degassed under nitrogen for 10 minutes. [1,1'-Bis(diphenylphosphino)ferrocene]dichloropalladium(II) (722 mg, 0.986 mmol) was added. The reaction mixture was heated at 100 °C for 20 hours. The reaction mixture was quenched with water, and extracted with CH₂Cl₂ (3 x 100 mL). The combined organic layers were washed with water, brine, dried over Na₂SO₄, filtered, and concentrated. The crude material was purified by flash chromatography (silica gel, 120 g, 0% to 30% ethyl acetate in hexanes). [2-Fluoro-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzyl]-carbamic acid tert-butyl ester (5.8 g, 100%) was obtained as a yellow oil.
Step 2: [4-(2,6-Dichloro-pyridin-4-yl)-2-fluoro-benzyl]-carbamic acid tert-butyl ester

In a microwave tube, 2,6-dichloro-4-iodopyridine (4.49 g, 16.4 mmol) and tetrakis(triphenylphosphine)palladium(0) (948 mg, 820 µmol) were combined with DMF (60 mL) to give a yellow solution. Potassium carbonate (6.8 g, 49.2 mmol) and [2-fluoro-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzyl]-carbamic acid tert-butyl ester (5.76 g, 16.4 mmol) were added. The reaction was heated in microwave reactor at 150 °C for 90 minutes. The reaction mixture was quenched with water and then extracted with CH₂Cl₂ (3x). The combined CH₂Cl₂ layers were washed with water, brine, dried over Na₂SO₄, filtered, and concentrated. The crude material was purified by flash chromatography (silica gel, 40 g, 0-25% ethyl acetate in hexanes). The product [4-(2,6-dichloro-pyridin-4-yl)-2-fluoro-benzyl]-carbamic acid tert-butyl ester (4.0 g, 59%) was obtained as a yellow solid.
Step 3: [4-(2-Chloro-6-methoxy-pyridin-4-yl)-2-fluoro-benzyl]-carbamic acid tert-butyl ester

In a pressure tube, [4-(2,6-dichloro-pyridin-4-yl)-2-fluoro-benzyl]-carbamic acid tert-butyl ester (3.99 g, 10.7 mmol) was combined with MeOH (46 mL) to give a colorless solution. Sodium methoxide (25 wt% NaOMe in methanol solution) (6.97 g, 7.37 mL, 32.2 mmol) was added. The reaction mixture was heated at reflux overnight. The reaction mixture was concentrated, and the crude material was purified by flash chromatography (silica gel, 0% to 25% ethyl acetate in hexanes). [4-(2-Chloro-6-methoxy-pyridin-4-yl)-2-fluoro-benzyl]-carbamic acid tert-butyl ester (2.72 g, 69%) was obtained as an off-white solid.

Step 4: [2-Fluoro-4-[2-methoxy-6-(1-methyl-1H-pyrazol-4-yl)-pyridin-4-yl]-benzyl]-carbamic acid tert-butyl ester

In a pressure tube, [4-(2-chloro-6-methoxy-pyridin-4-yl)-2-fluoro-benzyl]-carbamic acid tert-butyl ester (120 mg, 0.330 mmol), and tetrakis(triphenylphosphine)palladium(0) (38 mg, 0.033 mmol) were combined with DMF (4 mL) to give a light yellow solution. Potassium carbonate and 1-methyl-4-(4,4,5,5,-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (68 mg, 0.330 mmol) were added. The reaction mixture was stirred and heated at 100 °C overnight. In the morning,
more tetrakis(triphenylphosphine)palladium(0) (38 mg, 0.033 mmol) and l-methyl-4-(4,4,5,5,-
tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (68 mg, 0.330 mmol) were added. The
reaction mixture was heated at 150 °C using microwave irradiation for 2 hours. The reaction
mixture was cooled to room temperature and then diluted with water. The mixture was extracted
with CH₂Cl₂ (3 x 20 mL). The combined organic layers were washed with water, followed by
brine. The organic extracts were then dried over Na₂SO₄, filtered, and concentrated. The crude
material was purified using flash chromatography (12 g silica gel, 0-20% EtOAc in hexanes) to
yield {2-fluoro-4-[2-methoxy-6-(1-methyl-1H-pyrazol-4-yl)-pyridin-4-yl]-benzyl} -carbamic
acid tert-butyl ester (85 mg, 52%) as a white solid.

Step 5: 2-Fluoro-4-[2-methoxy-6-(1-methyl-1H-pyrazol-4-yl)-pyridin-4-yl]-benzylamine

In a 10 mL round-bottomed flask, {2-fluoro-4-[2-methoxy-6-(1 -methyl-1H-pyrazolo-1-4-y1)-
pyridin-4-yl]-benzyl} -carbamic acid tert-butyl ester (45 mg, 109 µmol) was combined with
CH₂Cl₂ (560 µL) and TFA to give a light yellow solution. The mixture was stirred at room
temperature for 2 hours. After this time, the reaction mixture was concentrated and the product
was further dried down on the high vacuum for 2 hours. The resulting product 2-fluoro-4-[2-
methoxy-6-(1 -methyl-1H-pyrazol-4-yl)-pyridin-4-yl]-benzylamine (32 mg, 73%) was used in
subsequent reactions without further purification.
Preparative Examples

Example 1-1

6-tert-Butyl-8-fluoro-2-[4-(2-oxo-1,2-dihydro-pyridin-4-yl)-benzyl]-2H-phthalazin-1-one

5 Step 1: 2-(4-Bromo-benzyl)-6-tert-butyl-8-fluoro-2H-phthalazin-1-one

6-tert-Butyl-8-fluoro-2H-phthalazin-1-one (which may be prepared as described in Berthel, S. et al. US 20100222325 Column 139; 50 mg, 0.23 mmol) and 1-bromo-4-chloromethyl-benzene (available from Aldrich; 51.4 mg, 0.25 mmol) were reacted using conditions analogous to those described in Example 1-2 Step 1 to give 2-(4-bromo-benzyl)-6-tert-butyl-8-fluoro-2H-phthalazin-1-one (80 mg, 90%) as a yellow oil.

Step 2: 6-tert-Butyl-8-fluoro-2-[4-(2-methoxy-pyridin-4-yl)-benzyl]-2H-phthalazin-1-one

A mixture of 2-(4-bromo-benzyl)-6-tert-butyl-8-fluoro-2H-phthalazin-1-one (80 mg, 0.21 mmol) and Pd(PPh₃)₄ (1 mol%) in DME was purged with argon for 10 min. Aqueous Na₂CO₃ solution (2 M; 2 eq) was added and the tube was purged again with argon. The solution was stirred at room temperature for 5 min and a solution of 2-methoxy-pyridine-4-boronic acid (available from Oakwood Products, Inc., 1741 Old Dunbar Road, West Columbia, SC 29172, USA; 39.3 mg,
Step 3: 6-tert-Butyl-8-fluoro-2-[4-(2-oxo-1,2-dihydro-pyridin-4-yl)-benzyl]-2H-phthalazin-1-one

6-tert-Butyl-8-fluoro-2-[4-(2-methoxy-pyridin-4-yl)-benzyl]-2H-phthalazin-1-one (100.0 mg, 0.24 mmol) was reacted with PBr₃ using the conditions described for Example 1-7 Step 4 to give 6-tert-butyl-8-fluoro-2-[4-(2-oxo-1,2-dihydro-pyridin-4-yl)-benzyl]-2H-phthalazin-1-one (50 mg, 52%) as a white solid. MS calcd. for C_{25}H_{25}F_{3}N_{2} [(M+H)^+] 404, obsd. 404. ¹H NMR (400 MHz, DMSO-d6) δ ppm 11.59 (br. s., 1 H), 8.45 (d, J=2.4 Hz, 1 H), 7.80 (d, J=1.5 Hz, 1 H), 7.72 (dd, J=13.2, 1.5 Hz, 1 H), 7.65 (d, J=8.3 Hz, 2 H), 7.34 - 7.46 (m, 3 H), 6.55 (d, J=1.5 Hz, 1 H), 6.46 (dd, J=6.8, 2.0 Hz, 1 H), 5.32 (s, 2 H), 1.35 (s, 9 H)

Example 1-2

6-tert-Butyl-8-fluoro-2-[2-fluoro-4-(2-oxo-1,2-dihydro-pyridin-4-yl)-benzyl]-2H-phthalazin-1-one
Step 1: 2-(4-Bromo-2-fluoro-benzyl)-6-tert-butyl-8-fluoro-2H-phthalazin-l-one

To a stirred suspension of NaH (60%, 55 mg, 1.36 mmol) in DMF (5 mL) was added dropwise a solution of 6-tert-butyl-8-fluoro-2H-phthalazin-l-one (which may be prepared as described in Berthel, S. et al. US 20100222325 Column 139; 150.0 mg, 0.68 mmol) in DMF (10 mL) at 0 °C. The mixture was heated to 70 °C and stirred for 30 min. The mixture was cooled to room temperature, a solution of 4-bromo-l-chloromethyl-2-fluoro-benzene (available from Aldrich; 167.3 mg, 0.75 mmol) in DMF (5 mL) was added and the mixture was stirred for 4 h at room temperature. Aqueous NH₄Cl solution was added. The mixture was extracted with EtOAc, and the EtOAc extract was dried, and evaporated. The residue was purified by chromatography (silica gel, 5% EtOAc/hexane) to give 2-(4-bromo-2-fluoro-benzyl)-6-tert-butyl-8-fluoro-2H-phthalazin-l-one (160 mg, 58%) as a white solid. MS calcd. for C₁₉H₁₈BrF₂N₂O [(M+H)⁺] 408, obsd. 408.

Step 2: 6-tert-Butyl-8-fluoro-2-[2-fluoro-4-(2-methoxy-pyridin-4-yl)-benzyl]-2H-phthalazin-l-one

2-(4-Bromo-2-fluoro-benzyl)-6-tert-butyl-8-fluoro-2H-phthalazin-l-one (160 mg, 0.39 mmol) was reacted with 2-methoxy-pyridine-4-boronic acid (available from Oakwood Products, Inc., 1741 Old Dunbar Road, West Columbia, SC 29172, USA; 60.4 mg, 0.49 mmol) using conditions analogous to those described in Example 1-1 Step 2 to give 6-tert-butyl-8-fluoro-2-[2-fluoro-4-(2-methoxy-pyridin-4-yl)-benzyl]-2H-phthalazin-l-one (80 mg, 47%) as a white solid.
Step 3: 6-tert-Butyl-8-fluoro-2-[2-fluoro-4-(2-oxo-1,2-dihydro-pyridin-4-yl)-benzyl]-2H-phthalazin-1-one

6-tert-Butyl-8-fluoro-2-[4-(2-methoxy-pyridin-4-yl)-benzyl]-2H-phthalazin-1-one (100.0 mg, 0.24 mmol) was reacted with PBr₃ using the conditions described for Example 1-7 Step 4 to give 6-tert-butyl-8-fluoro-2-[4-(2-oxo-1,2-dihydro-pyridin-4-yl)-benzyl]-2H-phthalazin-1-one (50 mg, 52%) as a white solid. MS calcd. for C₃₄H₂₂FN₃O₂ [(M+H)+] 422, obsd. 422.

H NMR (400 MHz, DMSO-d₆) δ ppm 11.64 (br. s., 1 H), 8.45 (d, J=2.4 Hz, 1 H), 7.80 (d, J=1.5 Hz, 1 H), 7.73 (dd, J=13.2, 1.5 Hz, 1 H), 7.59 (d, J=11.2 Hz, 1 H), 7.42 - 7.50 (m, 2 H), 7.32 (t, J=8.1 Hz, 1 H), 6.62 (d, J=1.5 Hz, 1 H), 6.50 (dd, J=6.8, 1.5 Hz, 1 H), 5.36 (s, 2 H), 1.35 (s, 9 H)

Example 1-3

6-tert-Butyl-8-fluoro-2-[2-hydroxymethyl-3-(2-oxo-1,2-dihydro-pyridin-4-yl)-phenyl]-2H-phthalazin-1-one

Step 1: 2-Bromo-6-(6-tert-butyl-8-fluoro-1-oxo-1H-phthalazin-2-yl)-benzaldehyde

To a stirred solution of 6-tert-butyl-8-fluoro-2H-phthalazin-1-one (which may be prepared as described in Berthel, S. et al. US 20100222325 Column 139; 100 mg, 0.45 mmol) in DMF (5 mL) were added 2-bromo-6-fluoro-benzaldehyde (available from Aldrich; 101.5 mg, 0.5 mmol),
cesium carbonate (325 mg, 0.27 mmol) and methoxymethylsilane (0.1 mL, 0.91 mmol). The mixture was heated at 60 °C for 4 h, then cooled to room temperature and diluted with water (25 mL). The resulting mixture was extracted with ethyl acetate, dried (Na$_2$SO$_4$), filtered, and evaporated. The residue was purified by chromatography (silica gel, 10% EtOAc/hexane) to give 2-bromo-6-(6-tert-butyl-8-fluoro-1-oxo-1H-phthalazin-2-yl)-benzaldehyde (105 mg, 57%) as a yellow gum. MS calcd. for C$_{19}$H$_{17}$BrFN$_2$O$_2$ [(M+H)$^+$] 404, obsd. 404.

**Step 2: 2-(3-Bromo-2-hydroxymethyl-phenyl)-6-tert-butyl-8-fluoro-2H-phthalazin-1-one**

![Chemical Structure](image)

To a stirred and cooled (~0 °C) solution of 2-bromo-6-(6-tert-butyl-8-fluoro-1-oxo-1H-phthalazin-2-yl)-benzaldehyde (100 mg, 0.25 mmol) in a mixture of CH$_2$C$_2$ and iPrOH (2:1; 7.5 mL) was added NaBH$_4$ (4.5 mg, 0.12 mmol). The mixture was stirred for 30 min at about 0 °C, then water was added and the mixture was extracted with EtOAc. The EtOAc extract was dried (Na$_2$SO$_4$), filtered, and evaporated. The residue was purified by chromatography (silica gel, 20% EtOAc/hexane) to give 2-(3-bromo-2-hydroxymethyl-phenyl)-6-tert-butyl-8-fluoro-2H-phthalazin-1-one (90 mg, 84%) as a white solid. MS calcd. for C$_{19}$H$_{17}$BrFN$_2$O$_2$ [(M+H)$^+$] 406, obsd. 406.

**Step 3: 6-tert-Butyl-8-fluoro-2-[2-hydroxymethyl-3-(2-methoxy-pyridin-4-yl)-phenyl]-2H-phthalazin-1-one**

![Chemical Structure](image)

To a stirred solution of 2-(3-bromo-2-hydroxymethyl-phenyl)-6-tert-butyl-8-fluoro-2H-phthalazin-1-one (90 mg, 0.22 mmol) in 20% aqueous dioxane (20 mL) were added 2-methoxypyridine-4-boronic acid (available from Oakwood Products, Inc., 1741 Old Dunbar Road, West Columbia, SC 29172, USA; 40.8 mg, 0.27 mmol), K$_2$CO$_3$ (61.3 mg, 0.44 mmol), and
tricyclohexylphosphine (3.7 mg, 0.01 mmol). The flask was evacuated and backfilled with nitrogen three times. Pd(dba)$_2$ (6.1 mg, 0.01 mmol) was added and the mixture was heated at 96 °C for 5 h. The mixture was cooled to room temperature and the solvents were evaporated. The residue was purified by chromatography (silica gel, 20% EtOAc/hexane) to give 6-tert-butyl-8-fluoro-2-[2-hydroxymethyl-3-(2-methoxy-pyridin-4-yl)-phenyl]-2H-phthalazin-l-one (60 mg, 62%) as a white solid. MS calcd. for C$_{25}$H$_{25}$FN$_3$O$_3$ [(M+H)$^+$] 434, obsd. 434.

Step 4: 6-tert-Butyl-8-fluoro-2-[2-hydroxymethyl-3-(2-oxo-1,2-dihydro-pyridin-4-yl)-phenyl]-2H-phthalazin-l-one

A mixture of 6-tert-butyl-8-fluoro-2-[2-hydroxymethyl-3-(2-methoxy-pyridin-4-yl)-phenyl]-2H-phthalazin-l-one (50 mg, 0.12 mmol), trimethylsilyl chloride (2 equivalents) and NaI (1 equivalent) in CH$_3$CN was heated at reflux for 2 h and then cooled to room temperature. 10% aqueous Na$_2$S$_2$O$_3$ solution was added and the mixture was made basic by the addition of saturated aqueous NaHCO$_3$. The mixture was extracted with 10% MeOH/CH$_2$Cl$_2$ and the organic extract was dried (Na$_2$SO$_4$), filtered, and evaporated. The residue was purified by chromatography (silica gel, MeOH/CH$_2$Cl$_2$) to give 6-tert-butyl-8-fluoro-2-[2-hydroxymethyl-3-(2-oxo-1,2-dihydro-pyridin-4-yl)-phenyl]-2H-phthalazin-l-one (23 mg, 48%) as a white solid. MS calcd. for C$_{24}$H$_{23}$FN$_3$O$_3$ [(M+H)$^+$] 420, obsd. 420.4. H NMR (400 MHz, DMSO-d$_6$) δ ppm

11.66 (br. s., 1 H), 8.51 (s, 1 H), 7.87 (s, 1 H), 7.74 (d, $J$=13.7 Hz, 1 H), 7.50 - 7.56 (m, 1 H), 7.36 - 7.48 (m, 3 H), 6.38 (s, 1 H), 6.30 (d, $J$=6.8 Hz, 1 H), 4.71 (t, $J$=5.1 Hz, 1 H), 4.29 (br. s., 2 H), 1.38 (s, 9 H).
Example 1-4

6-tert-Butyl-2-[2,6-difluoro-4-(2-oxo-1,2-dihydro-pyridin-4-yl)-benzyl]-8-fluoro-2H-phthalazin-1-one

Step 1: 5-Bromo-2-bromomethyl-1,3-difluoro-benzene

A mixture of 5-bromo-1,3-difluoro-2-methylbenzene  (available from Oakwood Products, Inc., 1741 Old Dunbar Road, West Columbia, SC 29172, USA; 1.0 g, 4.83 mmol), N-bromosuccinimide (0.86 g, 4.83 mmol) and AIBN (40 mg, 0.24 mmol) in CCl₄ (15 mL) was heated at reflux overnight. The mixture was filtered through Celite and the solvent was evaporated. The residue was purified by chromatography (silica gel, 2% EtOAc/hexane) to give 5-bromo-2-bromomethyl-1,3-difluoro-benzene  (1.1 g, 79%) as a colorless liquid.

Step 2: 2-(4-Bromo-2,6-difluoro-benzyl)-6-tert-butyl-8-fluoro-2H-phthalazin-1-one

To a stirred suspension of NaH (60%, 182 mg, 4.54 mmol) in DMF (1 mL) was added dropwise a solution of 6-tert-butyl-8-fluoro-2H-phthalazin-1-one  (which may be prepared as described in Berthel, S. et al. US 20100222325 Column 139; 500 mg, 2.27 mmol) in DMF (1.5 mL) at 0 °C. The mixture was heated to 70 °C and stirred for 30 min. The mixture was cooled to room temperature, a solution of 5-bromo-2-bromomethyl-1,3-difluoro-benzene  (715 mg, 2.5 mmol) in DMF (1.5 mL) was added and the mixture was stirred for 4 h at room temperature. The mixture
was cooled and cold water (5 mL) was added. The mixture was extracted with EtOAc and the organic extract was dried, and evaporated. The residue was purified by chromatography (silica gel, 5-10% EtOAc/hexane) to give 2-(4-bromo-2,6-difluoro-benzyl)-6-tert-butyl-8-fluoro-2H-phthalazin-1-one (555 mg, 57%) as a yellow solid. MS calcd. for C_{19}H_{17}BrF_{3}N_{2}O [(M+H)^+ ] 425, obsd. 425.

**Step 3: 6-tert-Butyl-2-[2,6-difluoro-4-(2-methoxy-pyridin-4-yl)-benzyl]-8-fluoro-2H-phthalazin-1-one**

![Chemical Structure](image)

A solution of 2-(4-bromo-2,6-difluoro-benzyl)-6-tert-butyl-8-fluoro-2H-phthalazin-1-one (550 mg, 1.29 mmol) in DME (1.6 mL) was purged with argon for 10 min. Pd(PPh\textsubscript{3})\textsubscript{4} (14 mg, 0.01 mmol) was added and the mixture was purged with argon for 10 min. Aqueous Na\textsubscript{2}CO\textsubscript{3} solution (2 M; 1.3 mL, 2.6 mmol) was added and the tube was purged with argon for 5 min. The solution was stirred at room temperature for 5 min and a solution of 2-methoxy-pyridine-4-boronic acid (available from Oakwood Products, Inc., 1741 Old Dunbar Road, West Columbia, SC 29172, USA; 245 mg, 1.61 mmol) in EtOH (1.6 mL) was added. The mixture was purged with argon for 10 min, capped, and heated at 90 °C for 1 h. The mixture was filtered through Celite and the Celite was washed with CH\textsubscript{2}C\textsubscript{12}. The filtrate was dried (Na\textsubscript{2}SO\textsubscript{4}), filtered and evaporated. The residue was purified by chromatography (silica gel, 15%> EtOAc/hexane) to give 6-tert-butyl-2-[2,6-difluoro-4-(2-methoxy-pyridin-4-y1)-benzyl]-8-fluoro-2H-phthalazin-1-one (420 mg, 71%) as a yellow solid. MS calcd. for C_{25}H_{23}F_{3}N_{3}O_{2} [(M+H)^+ ] 454, obsd. 454.

**Step 4: 6-tert-Butyl-2-[2,6-difluoro-4-(2-oxo-1,2-dihydro-pyridin-4-yl)-benzyl]-8-fluoro-2H-phthalazin-1-one**

![Chemical Structure](image)
A solution of 6-tert-butyl-2-[2,6-difluoro-4-(2-methoxy-pyridin-4-yl)-benzyl]-8-fluoro-2H-phthalazin-1-one (200 mg, 0.44 mmol) in CH\textsubscript{2}C\textsubscript{12} (15 mL) was cooled to 0 °C. BBr\textsubscript{3} (1M in CH\textsubscript{2}C\textsubscript{12}; 4.4 mL, 4.4 mmol) was added and the mixture was stirred at room temperature for 4 h. The mixture was cooled again to 0 °C and a further portion of BBr\textsubscript{3} (1M in CH\textsubscript{2}C\textsubscript{12}; 4.4 mL, 4.4 mmol) was added. The mixture was stirred at room temperature for 4 h and CH\textsubscript{2}C\textsubscript{12} (25 mL) was added. The mixture was washed with saturated aqueous NaHC\textsubscript{3} solution and the organic layer was dried (Na\textsubscript{2}SO\textsubscript{4}), filtered and evaporated. The residue was purified by chromatography (silica gel, 2-5% MeOH/CH\textsubscript{2}Cl\textsubscript{2}) to give 6-tert-butyl-2-[2,6-difluoro-4-(2-oxo-1,2-dihydro-pyridin-4-yl)-benzyl]-8-fluoro-2H-phthalazin-1-one (62 mg, 32%) as an off-white solid. MS calcd. for C\textsubscript{24}H\textsubscript{17}F\textsubscript{3}N\textsubscript{3}O\textsubscript{2} [(M+H)+] 440, obsd. 440. \textit{H} NMR (400 MHz, CDCl\textsubscript{3}) \( \delta \) ppm 11.67 (br. s., 1 H), 8.05 (d, \( J=2.4 \) Hz, 1 H), 7.37 - 7.42 (m, 3 H), 7.11 (d, \( J=7.8 \) Hz, 2 H), 6.71 (s, 1 H), 6.37 - 6.47 (m, 1 H), 5.49 (s, 2 H), 1.56 (s, 18 H), 1.36 (s, 9 H).

Example 1-5

6-tert-Butyl-8-fluoro-2-[2-hydroxymethyl-4-(2-oxo-1,2-dihydro-pyridin-4-yl)-benzyl]-2H-phthalazin-1-one

\begin{center}
\includegraphics[width=0.5\textwidth]{example.png}
\end{center}

Step 1: 5-Bromo-2-methyl-benzoic acid methyl ester

Thionyl chloride (10 mL) was added to 5-bromo-2-methyl-benzoic acid (2.0 g, 9.3 mmol) at 0 °C and then DMF (one drop) was added. The mixture was heated at reflux for 3 h under nitrogen. The reaction mixture was evaporated and dry MeOH (5 mL) was added to the residue. The mixture was concentrated, and EtOAc was added. The mixture was washed with saturated aqueous NaHC\textsubscript{3} solution and brine. The organic phase was dried (Na\textsubscript{2}SO\textsubscript{4}), filtered, and
evaporated to give 5-bromo-2-methyl-benzoic acid methyl ester (2.1 g, 98%) as an off-white solid.

Step 2: 5-Bromo-2-bromomethyl-benzoic acid methyl ester

\[
\begin{align*}
\text{Br} & \quad \text{O} \\
\text{Br} & \quad \text{Br}
\end{align*}
\]

A mixture of 5-bromo-2-methyl-benzoic acid methyl ester (500 mg, 2.19 mmol), N-bromosuccinimide (389 mg, 2.18 mmol) and AIBN (18 mg, 0.11 mmol) in \( \text{CCl}_4 \) (10 mL) was heated at reflux overnight. The reaction mixture was cooled, 5% aqueous \( \text{Na}_2\text{S}_2\text{O}_3 \) solution (5 mL) was added and the mixture was concentrated. The residue was diluted with EtOAc (30 mL) and the resulting mixture was washed with water (5 mL) and brine (5 mL). The organic phase was dried (\( \text{Na}_2\text{SO}_4 \)), filtered, and evaporated. The residue was purified by chromatography (silica gel, 0-1% EtOAc/hexane) to give 5-bromo-2-bromomethyl-benzoic acid methyl ester (600 mg, 89%).

Step 3: (5-Bromo-2-bromomethyl-phenyl)-methanol

\[
\begin{align*}
\text{Br} & \quad \text{OH} \\
\text{Br} & \quad \quad \quad \quad \\
\end{align*}
\]

A solution of 5-bromo-2-bromomethyl-benzoic acid methyl ester (200 mg, 0.65 mmol) in toluene (1.4 mL) was added dropwise to a solution of DIBAL-H (25% w/w in toluene; 0.87 mL, 1.3 mmol) in toluene (1.4 mL) at 0 °C under nitrogen. The reaction mixture was stirred at 0 °C for 2 h, and then acidified to pH 1 by the addition of 1 M HCl. The mixture was extracted with EtOAc (3 x 25 mL), and the combined organic extracts were washed with brine, dried (\( \text{Na}_2\text{SO}_4 \)), filtered, and evaporated to give (5-bromo-2-bromomethyl-phenyl)-methanol (143 mg, 78%) as an off-white solid.
Step 4: 2-(4-Bromo-2-hydroxymethyl-benzyl)-6-tert-butyl-8-fluoro-2H-phthalazin-l-one

NaH (60%, 80 mg, 2 mmol) was added to a solution of 6-tert-butyl-8-fluoro-2H-phthalazin-l-one (which may be prepared as described in Berthel, S. et al. US 20100222325 Column 139; 220 mg, 1 mmol) in DMF (2 mL) at 0 °C. The mixture was stirred for 5 min at 0 °C and then heated at 70 °C for 30 min. The mixture was cooled to room temperature, a solution of (5-bromo-2-bromomethyl-phenyl)-methanol (140 mg, 0.5 mmol) was added and the mixture was stirred for 1 h at room temperature. Ice-water (2 mL) was added. The mixture was extracted with EtOAc (3 x 25 mL). The EtOAc extract was washed with water (3 x 5 mL) and brine (5 mL), dried (Na₂SO₄), filtered, and evaporated. The residue was purified by preparative HPLC to give 2-(4-bromo-2-hydroxymethyl-benzyl)-6-tert-butyl-8-fluoro-2H-phthalazin-l-one (62 mg, 15%) as a yellow gum. MS calcd. for C₃₂H₂iBrFN₂0₂ [(M+H)+] 419, obsd. 418.8.

Step 5: 6-tert-Butyl-8-fluoro-2-[2-hydroxymethyl-4-(2-methoxy-pyridin-4-yl)-benzyl]-2H-phthalazin-l-one

To a stirred solution of 2-(4-bromo-2-hydroxymethyl-benzyl)-6-tert-butyl-8-fluoro-2H-phthalazin-l-one (60 mg, 0.143 mmol) in 20% aqueous dioxane (11 mL) were added 2-methoxy-pyridine-4-boronic acid (available from Oakwood Products, Inc., 1741 Old Dunbar Road, West Columbia, SC 29172, USA; 26 mg, 0.17 mmol), K₂CO₃ (39 mg, 0.29 mmol), and tricyclohexylphosphine (2 mg, 0.006 mmol). The mixture was purged with argon for 20 min and Pd₂(dba)₃ (5 mg, 0.006 mmol) was added. The mixture was heated at 100 °C for 4 h. The mixture was concentrated and EtOAc (30 mL) was added. The resulting mixture was washed with water (3 x 5 mL) and brine (5 mL). The organic layer was dried (Na₂SO₄), filtered, and...
evaporated. The residue was purified by chromatography (silica gel, 10% EtOAc/hexane) to give 6-tert-butyl-8-fluoro-2-[2-hydroxymethyl-4-(2-methoxy-pyridin-4-yl)-benzyl]-2H-phthalazin-1-one (54 mg, 84%) as a yellow gum. MS calcd. for C_{28}H_{26}FN_{3}O_{3} [(M+H)^+] 448, obsd. 447.8.

Step 6: 6-tert-Butyl-8-fluoro-2-[2-hydroxymethyl-4-(2-oxo-1,2-dihydro-pyridin-4-yl)-benzyl]-2H-phthalazin-1-one

A mixture of 6-tert-butyl-8-fluoro-2-[2-hydroxymethyl-4-(2-methoxy-pyridin-4-yl)-benzyl]-2H-phthalazin-1-one (260 mg, 0.58 mmol), trimethylsilyl chloride (0.12 g, 1.1 mmol) and NaI (122 mg, 0.81 mmol) in CH_{3}CN (15 mL) was heated at reflux under nitrogen for 3 h and then cooled to room temperature. 5% aqueous Na_{2}S_{2}O_{3} solution (5 mL) was added and the mixture was made basic by the addition of saturated aqueous NaHCO_{3} (5 mL). The mixture was concentrated and EtOAc (50 mL) was added. The resulting mixture was washed with water (5 mL) and brine, dried (Na_{2}SO_{4}), filtered, and evaporated. The residue was purified by chromatography (silica gel, 2-5% MeOH/CH_{2}Cl_{2}) to give 6-tert-butyl-8-fluoro-2-[2-hydroxymethyl-4-(2-oxo-1,2-dihydro-pyridin-4-yl)-benzyl]-2H-phthalazin-1-one (60 mg, 24%) as an off-white solid. MS calcd. for C_{24}H_{23}FN_{3}O_{3} [(M+H)^+] 434, obsd. 434.4. \text{H NMR (400 MHz, DMSO-\text{d}_{6})} \delta \text{ ppm 11.59 (br. s., 1 H), 8.46 (d, } J=2.4 \text{ Hz, 1 H), 7.81 (d, } J=1.5 \text{ Hz, 1 H), 7.69 - 7.76 (m, 2 H), 7.50 (dd, } J=8.3, 2.0 \text{ Hz, 1 H), 7.44 (d, } J=6.8 \text{ Hz, 1 H), 7.10 (d, } J=7.8 \text{ Hz, 1 H), 6.53 (s, 1 H), 6.46 (d, } J=7.3 \text{ Hz, 1 H), 5.36 (s, 2 H), 5.29 (t, } J=5.4 \text{ Hz, 1 H), 4.72 (d, } J=5.4 \text{ Hz, 2 H), 1.36 (s, 9 H).}
Example 1-6

6-tert-Butyl-8-fluoro-2-[2-fluoro-4-[6-(1-methyl-1H-pyrazol-4-yl)-2-oxo-1,2-dihydro-pyridin-4-yl]-benzyl]-2H-phthalazin-1-one

Step 1: 4-Bromo-l-bromomethyl-2-fluoro-benzene

A mixture of 4-bromo-2-fluoro-l-methylbenzene (available from Aldrich; 2.0 g, 10.58 mmol), N-bromosuccinimide (1.88 g, 10.58 mmol) and AIBN (87 mg, 0.53 mmol) in CCl₄ (30 mL) was heated at reflux under nitrogen for 4 h. The reaction mixture was cooled to room temperature, 5% aqueous Na₂S₂O₃ solution was added and the mixture was concentrated. Water (10 mL) was added and the mixture was extracted with EtOAc (3 x 50 mL). The combined organic phases were dried (Na₂SO₄), filtered, and evaporated. The residue was purified by chromatography (silica gel, hexane) to give 4-bromo-l-bromomethyl-2-fluoro-benzene (1.5 g, 53%) as a colorless liquid.

Step 2: 2-(4-Bromo-2-fluoro-benzyl)-6-tert-butyl-8-fluoro-2H-phthalazin-1-one
To a suspension of NaH (60%, 473 mg, 11.8 mmol) in DMF (5 mL) was added a solution of 6-tert-butyl-8-fluoro-2H-phthalazin-l-one (which may be prepared as described in Berthel, S. et al. US 20100222325 Column 139; 1.3 g, 5.91 mmol) at 0 °C. The mixture was stirred for 5 min at 0 °C and heated at 70 °C for 30 min under nitrogen. The mixture was cooled to room temperature, a solution of 4-bromo-1-bromomethyl-2-fluoro-benzene (1.74 g, 6.5 mmol) in DMF (3 mL) was added and the mixture was stirred for 1.5 h at room temperature. Cold water (5 mL) was added. The mixture was extracted with EtOAc and the organic extract was dried (Na₂SO₄), and evaporated. The residue was purified by chromatography (silica gel, 20% EtOAc/hexane) to give 2-(4-bromo-2-fluoro-benzyl)-6-tert-butyl-8-fluoro-2H-phthalazin-l-one (1.0 g, 41%) as a yellow solid. MS calc. for Cl₈H₁₂BrF₂N₂O [(M+H)+] 407, obsd. 407.2.

**Step 3: 6-tert-Butyl-2-[4-(2,6-dichloro-pyridin-4-yl)-2-fluoro-benzyl]-8-fluoro-2H-phthalazin-l-one**

![](image.png)

A solution of 2-(4-bromo-2-fluoro-benzyl)-6-tert-butyl-8-fluoro-2H-phthalazin-l-one (500 mg, 1.22 mmol), 4,4,5,5,4',4',5',5'-octamethyl-[2,2']bi[[1,3,2]dioxaborolanyl] (available from Aldrich; 405 mg, 1.58 mmol) and dry KOAc (361 mg, 3.67 mmol) in dioxane (16 mL) was degassed under argon. X-Phos (available from Aldrich; 87 mg, 0.18 mmol) and Pd(OAc)₂ (13 mg, 0.061 mmol) were added and the mixture was heated at 95 °C for 40 min. The bath temperature was lowered to 80 °C and the reaction flask was raised out of the heating bath with stirring maintained. 2,6-Dichloro-4-ido-pyridine (available from Aldrich; 300 mg, 1.09 mmol) and K₂CO₃ (507 mg, 3.67 mmol) were added. Water (3.4 mL) that had been degassed with argon was added. The reaction mixture was degassed with argon. Tricyclohexylphosphine (51 mg, 0.18 mmol) and Pd₂(dba)₃ (56 mg, 0.061 mmol) were added and the mixture was stirred at 80 °C for 14 h. The mixture was filtered through Celite and the Celite was washed with EtOAc (3 x 25 mL). The filtrate was evaporated with CH₂Cl₂ (50 mL) was added. The resulting mixture was washed with water and brine. The organic layer was dried (Na₂SO₄), filtered, and evaporated. The residue was purified by chromatography (silica gel, 30% EtOAc/hexane) to give 6-tert-
butyl-2-[4-(2,6-dichloro-pyridin-4-yl)-2-fluoro-benzyl]-8-fluoro-2H-phthalazin-1-one (260 mg, 44%) as a yellow solid. MS calcd. for C$_{24}$H$_{20}$Cl$_2$F$_2$N$_3$O [(M+H)$^+$] 474, obsd. 474.

**Step 4: 6-tert-Butyl-2-[4-2-chloro-6-(1-methyl-1H-pyrazol-4-yl)-pyridin-4-yl]-2-fluoro-benzyl]-8-fluoro-2H-phthalazin-1-one**

A mixture of 6-tert-butyl-2-[4-(2,6-dichloro-pyridin-4-yl)-2-fluoro-benzyl]-8-fluoro-2H-phthalazin-1-one (160 mg, 0.34 mmol), 1-methyl-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-pyrazole (available from Aldrich; 56 mg, 0.27 mmol), K$_2$CO$_3$ (140 mg, 1.01 mmol) and DMF (3 mL) in a sealable tube was purged with argon for 30 min. Pd(PPh$_3$)$_4$ (39 mg, 0.03 mmol) was added and the mixture was purged for 10 min. The tube was sealed and heated at 100 °C for 16 h. The reaction mixture was cooled, diluted with water (5 mL) and extracted with EtOAc (3 x 20 mL). The organic layer was dried (Na$_2$SO$_4$), filtered, and evaporated. The residue was purified by chromatography (silica gel, 20-50% EtOAc/hexane) to give 6-tert-butyl-2-[4-[2-chloro-6-(1-methyl-1H-pyrazol-4-yl)-pyridin-4-yl]-2-fluoro-benzyl]-8-fluoro-2H-phthalazin-1-one (65 mg, 37%) as a yellow gum. MS calcd. for C$_{28}$H$_{25}$ClF$_2$N$_5$O [(M+H)$^+$] 520, obsd. 520.

**Step 5: 6-tert-Butyl-8-fluoro-2-[2-fluoro-4-[6-(1-methyl-1H-pyrazol-4-yl)-2-oxo-1,2-dihydro-pyridin-4-yl]-benzyl]-2H-phthalazin-1-one**
A mixture of 6-tert-butyl-2-{4-[2-chloro-6-(1-methyl-1H-pyrazol-4-yl)-pyridin-4-yl]-2-fluoro-benzyl}-8-fluoro-2H-phthalazin-1-one (65 mg, 0.125 mmol) and 10 M HCl (7 mL) was heated at 130 °C for 96 h. The reaction mixture was concentrated and ice-water (5 mL) was added to the residue. The resulting mixture was neutralized by the addition of saturated aqueous NaHCO₃ solution. The mixture was extracted with EtOAc (3 x 25 mL). The combined organic layers were dried (Na₂SO₄), filtered, and evaporated. The residue was purified by preparative HPLC (Column = XTerra C18 (250 x 9 mm) 10μ, Flow rate = 14.0 mL/min, 5 mM NH₄OAc in water, CH₃CN) to give 6-tert-butyl-8-fluoro-2-{2-fluoro-4-[6-(1-methyl-1H-pyrazol-4-yl)-2-oxo-1,2-dihydro-pyridin-4-yl]-benzyl}-2H-phthalazin-1-one (17 mg, 27%) as an off-white solid. MS calcd. for C₂₉H₂₆F₂N₂O₂ [(M+H)⁺] 502, obsd. 502.4. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 11.72 (s, 1 H), 8.45 (d, J=2.4 Hz, 1 H), 8.41 (s, 1 H), 8.15 (s, 1 H), 7.80 (s, 1 H), 7.63 - 7.76 (m, 2 H), 7.55 (d, J=8.3 Hz, 1 H), 7.35 (t, J=8.1 Hz, 1 H), 6.86 (br. s., 1 H), 6.46 (s, 1 H), 5.38 (s, 2 H), 3.87 (s, 3 H), 1.36 (s, 9 H).

Example 1-7

**4-tert-Butyl-N-[2-methyl-3-(2-oxo-1,2-dihydro-pyridin-4-yl)-phenyl]-benzamide**

**Step 1: 2-Methoxy-4-(2-methyl-3-nitro-phenyl)-pyridine**

4-Bromo-2-methoxy-pyridine (available from Oakwood Products, Inc., 1741 Old Dunbar Road, West Columbia, SC 29172, USA; 500 mg, 2.26 mmol) was reacted with 2-methyl-3-nitrophenylboronic acid (available from Combi-Blocks Inc., 7949 Silverton Avenue, Suite 915, San Diego, CA 92126, USA; 60.4 mg, 0.49 mmol) using conditions analogous to those described in Example 1-1 Step 2 to give 2-methoxy-4-(2-methyl-3-nitro-phenyl)-pyridine (420 mg, 65%) as a white solid.
Step 2: 3-(2-Methoxy-pyridin-4-yl)-2-methyl-phenylamine

A mixture of 2-methoxy-4-(2-methyl-3-nitro-phenyl)-pyridine (100 mg, 0.41 mmol) and 10% palladium-on-carbon (10 mg) in MeOH (10 mL) was hydrogenated using a hydrogen balloon at room temperature for 2 h. The mixture was filtered through Celite and the Celite was washed with MeOH. The combined filtrates were evaporated to give 3-(2-methoxy-pyridin-4-yl)-2-methyl-phenylamine (80 mg, 91%) as a white solid. MS calcd. for C_{13}H_{15}N_{2}O [(M+H)^+] 215, obsd. 215.
Step 3: 4-tert-Butyl-N- [3-(2-methoxy-pyridin-4-yl)-2-methyl-phenyl] -benzamide

A solution of 4-tert-butyl-benzoic acid (available from Aldrich; 197 mg, 1.12 mmol) in CH₂Cl₂ (15 mL), triethylamine (0.14 mL, 2.8 mmol) and HATU (available from Aldrich; 532 mg, 1.4 mmol) was stirred at room temperature for 30 min. 3-(2-Methoxy-pyridin-4-yl)-2-methyl-phenylamine (200 mg, 0.93 mmol) was added and the mixture was stirred at room temperature for 18 h. Saturated aqueous NaHCO₃ solution was added. The organic phase was separated, dried (Na₂SO₄), filtered, and evaporated. The residue was purified by chromatography (silica gel, 10% EtOAc/hexane) to give 4-tert-butyl-N- [3-(2-methoxy-pyridin-4-yl)-2-methyl-phenyl] -benzamide (110 mg, 31%) as a yellow gum. MS calcd. for C₂₄H₂₇N₂O₂ [(M+H)+] 375, obsd. 375.

Step 4: 4-tert-Butyl-N- [2-methyl-3-(2-oxo-1,2-dihydro-pyridin-4-yl)-phenyl] -benzamide

To a stirred solution of 4-tert-butyl-N- [3-(2-methoxy-pyridin-4-yl)-2-methyl-phenyl] -benzamide (115 mg, 0.3 mmol) in 1,2-dichloroethane (15 mL) at 0 °C was slowly added PBr₃ (97.7 mg, 0.89 mmol). The mixture was heated at reflux for 4 h. Ice water was added, followed by 10% aqueous NaHCO₃ solution (5 mL). The mixture was extracted with 5% MeOH/CH₂Cl₂ and the organic extract was dried (Na₂SO₄), filtered, and evaporated. The residue was purified by chromatography (silica gel, 5% MeOH/CH₂Cl₂) to give 4-tert-butyl-N-[2-methyl-3-(2-oxo-1,2-dihydro-pyridin-4-yl)-phenyl]-benzamide (15 mg, 14%) as a white solid. MS calcd. for C₂₃H₂₅N₂O₂ [(M+H)+] 361, obsd. 361. H NMR (400 MHz, CDCl₃) δ ppm 11.81 (br. s., 1 H), 7.96 (d, J=7.8 Hz, 1 H), 7.84 (d, J=8.3 Hz, 2 H), 7.71 (s, 1 H), 7.53 (d, J=8.8 Hz, 2 H), 7.30 - 7.39 (m, 2 H), 7.08 (d, J=7.3 Hz, 1 H), 6.52 (s, 1 H), 6.26 (dd, J=6.6, 1.7 Hz, 1 H), 2.25 (s, 3 H), 1.36 (s, 9 H).
Example 1-8

6-tert-Butyl-8-fluoro-2-[3-hydroxymethyl-4-(2-oxo-1,2-dihydro-pyridin-4-yl)-benzyl]-2H-phthalazin-1-one

Step 1: 2-Bromo-5-bromomethyl-benzoic acid

A mixture of 2-bromo-5-methyl-benzoic acid (available from Aldrich; 1.0 g, 4.65 mmol), N-bromosuccinimide (1.24 g, 6.98 mmol) and benzoyl peroxide (23 mg, 0.09 mmol) in CH₃CN (30 mL) was heated at reflux overnight. The reaction mixture was concentrated, and the residue was purified by chromatography (silica gel, 10% EtOAc/hexane) to give 2-bromo-5-bromomethyl-benzoic acid (1.2 g, 87%) as a light yellow solid. MS calcd. for C₇H₇Br₂O₂ [(M+H)+] 293, obsd. 293. This material was used directly in the next step although NMR shows the presence of a small impurity.

Step 2: (2-Bromo-5-bromomethyl-phenyl)-methanol

BH₃-DMS (2 M solution in THF, 6.1 mL, 12.2 mmol) was added under nitrogen to a 0 ºC solution of 2-bromo-5-bromomethyl-benzoic acid (1.2 g, 4.08 mmol) in THF (15 mL). The mixture was stirred overnight at room temperature. MeOH and ice-water were added and the mixture was concentrated. EtOAc (100 mL) was added and the mixture was washed with water (10 mL) and brine (10 mL). The organic layer was dried (Na₂SO₄), filtered, and evaporated to
give crude (2-bromo-5-bromomethyl-phenyl)-methanol (1.2 g) as a white solid which was used directly in the next step without purification.

**Step 3: 1-Bromo-4-bromomethyl-2-methoxymethoxymethyl-benzene**

To a cooled (0 °C) solution of crude (2-bromo-5-bromomethyl-phenyl)-methanol (from Step 2; 0.95 g, 3.4 mmol) in CH₂C₁₂ (30 mL) were added DIPEA (0.66 g, 5.1 mmol) and methyl chloromethyl ether (0.34 g, 4.24 mmol) under nitrogen. The mixture was stirred overnight at room temperature. CH₂C₁₂ (50 mL) was added and the mixture was washed with aqueous NaHCO₃ solution. The organic extract was dried (Na₂SO₄), filtered, and evaporated. The residue was purified by chromatography (silica gel, 2-5% EtOAc/hexane) to give 1-bromo-4-bromomethyl-2-methoxymethoxymethyl-benzene (275 mg, 25%) as a colorless liquid.

**Step 4: 2-(4-Bromo-3-methoxymethoxymethyl-benzyl)-6-tert-butyl-8-fluoro-2H-phthalazin-1-one**

To a suspension of NaH (60%, 145 mg, 3.63 mmol) in DMF (3 mL) was added dropwise a solution of 6-tert-butyl-8-fluoro-2H-phthalazin-1-one (which may be prepared as described in Berthel, S. et al. US 20100222325 Column 139; 400.0 mg, 1.82 mmol) in DMF (2 mL) at 0 °C. The mixture was stirred at room temperature for 5 min and then heated at 70 °C for 30 min. The mixture was cooled to room temperature, a solution of 1-bromo-4-bromomethyl-2-methoxymethoxymethyl-benzene (684 mg, 2 mmol) in DMF (2 mL) was added and the mixture was stirred for 4 h at room temperature. Water (5 mL) was added, and the mixture was extracted
with EtOAc (3 x 20 mL). The combined organic layers were washed with water (3 x 5 mL) and brine (5 mL), dried (Na₂SO₄), filtered, and evaporated. The residue was purified by chromatography (silica gel, 12% EtOAc/hexane) to give 2-(4-bromo-3-methoxymethoxymethyl-benzyl)-6-tert-butyl-8-fluoro-2H-phthalazin-1-one (230 mg, 27%) as a yellow gum. MS calcd. for C₂₂H₂₅BrFN₃O₃ [(M+H)⁺] 463, obsd. 462.8.

**Step 5: 6-tert-Butyl-8-fluoro-2-[3-methoxymethoxymethyl-4-(2-methoxy-pyridin-4-yl)-benzyl]-2H-phthalazin-1-one**

A solution of 2-(4-bromo-3-methoxymethoxymethyl-benzyl)-6-tert-butyl-8-fluoro-2H-phthalazin-1-one (185 mg, 0.4 mmol) in DME (1.5 mL) in a sealable tube was purged with argon for 10 min. Pd(PPh₃)₄ (5 mg, 0.004 mmol) was added and the mixture was purged with argon for 10 min. Aqueous Na₂CO₃ solution (0.4 mL, 0.8 mmol) was added and the tube was purged with argon for 5 min. The solution was stirred at room temperature for 5 min and a solution of 2-methoxy-pyridine-4-boronic acid (available from Oakwood Products, Inc., 1741 Old Dunbar Road, West Columbia, SC 29172, USA; 75 mg, 0.49 mmol) in EtOH (1.5 mL) was added. The mixture was purged with argon for 5 min, capped, and heated at 90 °C for 1 h. The mixture was filtered through Celite and the Celite was washed with CH₂C₂H₂. The filtrate was dried (Na₂SO₄), filtered and evaporated. The residue was purified by chromatography (silica gel, 15% EtOAc/hexane) to give 6-tert-butyl-8-fluoro-2-[3-methoxymethoxymethyl-4-(2-methoxy-pyridin-4-yl)-benzyl]-2H-phthalazin-1-one (65 mg, 33%) as a yellow gum. MS calcd. for C₂₈H₃₁FN₃O₄ [(M+H)⁺] 492, obsd. 492.2.
Step 6: 6-tert-Butyl-8-fluoro-2-[3-hydroxymethyl-4-(2-methoxy-pyridin-4-yl)-benzyl]-2H-phthalazin-1-one

A solution of 6-tert-butyl-8-fluoro-2-[3-methoxymethoxymethyl-4-(2-methoxy-pyridin-4-yl)-benzyl]-2H-phthalazin-1-one (68 mg, 0.138 mmol) in dioxane (10 mL) was cooled to 0 °C and a solution of 4 M HCl in dioxane (0.7 mL, 2.8 mmol) was added dropwise. The mixture was stirred at room temperature for 4 h and then the solvent was evaporated. Saturated aqueous NaHCO₃ was added to bring the pH to 8 and the mixture was extracted with EtOAc (3 x 15 mL). The combined EtOAc extracts were dried (Na₂SO₄), filtered, and evaporated to give crude 6-tert-butyl-8-fluoro-2-[3-hydroxymethyl-4-(2-methoxy-pyridin-4-yl)-benzyl]-2H-phthalazin-1-one (37 mg) as a gum which was used directly in the next step without further purification. MS calcd. for C₂₆H₂₇FN₃O₃ [(M+H)+] 448, obsd. 448.0.

Step 7: 6-tert-Butyl-8-fluoro-2-[3-hydroxymethyl-4-(2-oxo-1,2-dihydro-pyridin-4-yl)-benzyl]-2H-phthalazin-1-one

A mixture of crude 6-tert-butyl-8-fluoro-2-[3-hydroxymethyl-4-(2-methoxy-pyridin-4-yl)-benzyl]-2H-phthalazin-1-one (from Step 6; 37 mg, 0.08 mmol), trimethylsilyl chloride (0.017 g, 0.157 mmol) and NaI (17.4 mg, 0.12 mmol) in CH₃CN (5 mL) was heated at reflux for 3 h and then concentrated. Aqueous Na₂S₂O₃ solution (1 mL) was added, followed by saturated aqueous NaHCO₃ (2 mL). The mixture was extracted with CH₂Cl₂ (3 x 15 mL) and the combined organic layers were dried (Na₂SO₄), filtered, and evaporated. The residue was purified by chromatography (silica gel, 1-2% MeOH/CH₂Cl₂) to give 6-tert-butyl-8-fluoro-2-[3-hydroxymethyl-4-(2-oxo-1,2-dihydro-pyridin-4-yl)-benzyl]-2H-phthalazin-1-one (15 mg, 25%) as an off-white solid. MS calcd. for C₂₅H₂₅FN₃O₃ [(M+H)+] 434, obsd. 434.0. H NMR (400
MHz, CDCl3) δ ppm 10.78 (s, 1 H), 8.11 (d, J=2.4 Hz, 1 H), 7.64 (s, 1 H), 7.39 - 7.49 (m, 3 H), 6.53 (s, 1 H), 6.30 (d, J=5.9 Hz, 1 H), 5.39 (s, 2 H), 4.61 (s, 2 H), 1.37 (s, 9 H).

Example 1-9

6-tert-Butyl-8-fluoro-2-[2-fluoro-5-hydroxymethyl-4-(2-oxo-1,2-dihydro-pyridin-4-yl)-benzyl]-2H-phthalazin-1-one

Step 1: 2-Bromo-4-fluoro-5-methyl-benzoic acid

A mixture of 2-bromo-4-fluoro-5-methyl-benzoic acid (available from 3B Scientific Corporation, 1840 Industrial Drive, Suite 160, Libertyville, IL 60048, USA; 1.0 g, 4.61 mmol), sulfamic acid (2.68 g, 27.65 mmol), sodium chlorite (539 mg, 6 mmol) and KH2PO4 (7.52 g, 55.3 mmol) in 50% aqueous dioxane (96 mL) was stirred at room temperature overnight. The reaction mixture was concentrated, and water (20 mL) was added. The resulting mixture was extracted with EtOAc (3 x 250 mL). The combined organic layers were dried (Na2SO4), filtered, and evaporated to give 2-bromo-4-fluoro-5-methyl-benzoic acid (1.0 g, 93%) as an off-white solid. MS calcd. for C8H7BrF02 [(M-H)-] 231, obsd. 231.0.

Step 2: 2-Bromo-5-bromomethyl-4-fluoro-benzoic acid

A mixture of 2-bromo-4-fluoro-5-methyl-benzoic acid (0.5 g, 2.14 mmol), N-bromosuccinimide (381 mg, 2.15 mmol) and benzoyl peroxide (10 mg, 0.04 mmol) in CH3CN (10 mL) was heated
at reflux for 4 h. The reaction mixture was cooled to 0 °C and 5% aqueous Na₂S₂O₃ was added. The CH₃CN was evaporated and the residue was extracted with EtOAc (3 x 100 mL). The combined organic phases were dried (Na₂SO₄), filtered, and evaporated. The residue was purified by chromatography (silica gel, 2-20% EtOAc/hexane) to give 2-bromo-5-bromomethyl-4-fluoro-benzoic acid (500 mg, 74%). MS calcd. for C₈H₆Br₂F₀₂ [(M-H)⁻] 309, obsd. 308.6.

**Step 3: (2-Bromo-5-bromomethyl-4-fluoro-phenyl)-methanol**

\[ \text{BH}_3\text{-DMS (2 M solution in THF, 1.9 mL, 3.8 mmol) was added under nitrogen to a 0 °C solution of 2-bromo-5-bromomethyl-4-fluoro-benzoic acid (400 mg, 1.28 mmol) in THF (5 mL). The mixture was stirred overnight at room temperature. MeOH and ice-water were added and the mixture was concentrated. EtOAc (50 mL) was added and the mixture was washed with water (5 mL) and brine (5 mL). The organic layer was dried (Na₂SO₄), filtered, and evaporated to give (2-bromo-5-bromomethyl-4-fluoro-phenyl)-methanol (320 mg, 84%) as a white solid which was used directly in the next step without purification.} \]

**Step 4: 2-(4-Bromo-2-fluoro-5-hydroxymethyl-benzyl)-6-tert-butyl-8-fluoro-2H-phthalazin-1-one**

NaH (60%, 108 mg, 2.72 mmol) was added portionwise to a solution of 6-tert-butyl-8-fluoro-2H-phthalazin-1-one (which may be prepared as described in Berthel, S. et al. US 20100222325 Column 139; 300.0 mg, 1.36 mmol) in DMF (3 mL) at 0 °C. The mixture was heated at 70 °C for 30 min. The mixture was cooled to room temperature, a solution of (2-bromo-5-bromomethyl-4-fluoro-phenyl)-methanol (203 mg, 0.68 mmol) in DMF (2 mL) was added and the mixture was stirred for 2.5 h at room temperature. Water (5 mL) was added, and the mixture was extracted with EtOAc (3 x 15 mL). The combined organic layers were dried (Na₂SO₄).
filtered, and evaporated. The residue was purified by preparative HPLC to give 2-(4-bromo-2-fluoro-5-hydroxymethyl-benzyl)-6-tert-butyl-8-fluoro-2H-phthalazin-1-one (59 mg, 10%). MS calcd. for C_{26}H_{24}BrF_{2}N_{3}O_{3} [(M+H)^+] 437, obsd. 436.8.

**Step 5: 6-tert-Butyl-8-fluoro-2-[2-fluoro-5-hydroxymethyl-4-(2-methoxy-pyridin-4-yl)-benzyl]-2H-phthalazin-1-one**

![Chemical Structure](image)

To a stirred solution of 2-(4-bromo-2-fluoro-5-hydroxymethyl-benzyl)-6-tert-butyl-8-fluoro-2H-phthalazin-1-one (55 mg, 0.13 mmol) in 20% aqueous dioxane (11 mL) were added 2-methoxy-pyridine-4-boronic acid (available from Oakwood Products, Inc., 1741 Old Dunbar Road, West Columbia, SC 29172, USA; 23 mg, 0.153 mmol), K_{2}CO_{3} (35 mg, 0.25 mmol), and tricyclohexylphosphine (1 mg, 0.005 mmol). The mixture was purged with argon for 20 min and Pd_{2}(dba)_{3} (5 mg, 0.005 mmol) was added. The mixture was heated at 100 °C for 4 h. The mixture was concentrated and EtOAc (30 mL) was added. The resulting mixture was washed with water (3 x 5 mL) and brine (5 mL). The organic layer was dried (Na_{2}SO_{4}), filtered, and evaporated. The residue was purified by chromatography (silica gel, 10% EtOAc/hexane) to give 6-tert-butyl-8-fluoro-2-[2-fluoro-5-hydroxymethyl-4-(2-methoxy-pyridin-4-yl)-benzyl]-2H-phthalazin-1-one (56 mg, 95%) as a yellow gum. MS calcd. for C_{26}H_{26}F_{2}N_{3}O_{3} [(M+H)^+] 466, obsd. 466.0.

**Step 6: 6-tert-Butyl-8-fluoro-2-[2-fluoro-5-hydroxymethyl-4-(2-oxo-1,2-dihydro-pyridin-4-yl)-benzyl]-2H-phthalazin-1-one**

![Chemical Structure](image)

A mixture of 6-tert-butyl-8-fluoro-2-[2-fluoro-5-hydroxymethyl-4-(2-methoxy-pyridin-4-yl)-benzyl]-2H-phthalazin-1-one (55 mg, 0.12 mmol), trimethylsilyl chloride (24 mg, 0.22 mmol)
and Nal (25 mg, 0.17 mmol) in CH3CN (5 mL) was heated at reflux for 3 h and then evaporated. 5% aqueous Na2S2O3 solution (1 mL) was added, followed by saturated aqueous NaHCO3 (2 mL). The mixture was extracted with CH2Cl2 (3 x 15 mL) was added. The combined organic extracts were dried (Na2SO4), filtered, and evaporated. The residue was purified by chromatography (silica gel, 1-5% MeOH/CH2Cl2) to give 6-tert-butyl-8-fluoro-2-[2-fluoro-5-hydroxymethyl-4-(2-oxo-1,2-dihydro-pyridin-4-yl)-benzyl]-2H-phthalazin-1-one (33 mg, 62%) as an off-white solid. MS calcd. for C25H24F2N3O3 [(M+H)+] 452, obsd. 452.0. 1H NMR (400 MHz, DMSO-d6) δ ppm 11.67 (br. s., 1 H), 8.46 (d, J=2.4 Hz, 1 H), 7.81 (s, 1 H), 7.74 (d, J=13.2 Hz, 1 H), 7.37 - 7.44 (m, 2 H), 7.12 (d, J=10.3 Hz, 1 H), 6.28 (s, 1 H), 6.19 (d, J=6.4 Hz, 1 H), 5.36 (s, 2 H), 5.20 (t, J=5.4 Hz, 1 H), 4.32 (d, J=5.4 Hz, 2 H), 1.36 (s, 9 H).

Example I-10

2-tert-Butyl-5-[2-fluoro-4-[6-(1-methyl-1H-pyrazol-4-yl)-2-oxo-1,2-dihydro-pyridin-4-yl]-benzyl]-4,5-dihydro-thieno[2,3-c]pyrrol-6-one

\[
\begin{align*}
\text{HN} & \quad \text{O} \\
\text{N} & \quad \text{HN} \\
\text{O} & \quad \text{F} \\
\text{O} & \quad \text{O}
\end{align*}
\]

15 Step 1: 3-Methyl-thiophene-2-carboxylic acid methyl ester

A suspension of 3-methylthiophene-2-carboxylic acid (available from Aldrich; 15 g, 106 mmol) in MeOH (211 mL) was cooled to 0 °C. Concentrated sulfuric acid (6 ml, 113 mmol) was added dropwise and the mixture was stirred at room temperature for 3 days. The reaction mixture as concentrated and the residue was partitioned between EtOAc and saturated aqueous NaHCO3 solution. The organic phase was dried (Na2SO4), filtered, and concentrated to afford a brown oil
which contained a mixture of the desired methyl ester (84%) and the starting material (16%) by NMR. The crude product was dissolved in EtOAc and the solution was washed with 1 M aqueous NaOH. The organic phase was dried (MgSO₄), filtered, and evaporated to give 3-
methyl-thiophene-2-carboxylic acid methyl ester (13.6 g, 82%) as a light brown oil. H NMR (300 MHz, CDCls) δ ppm 7.39 (d, J=5.09 Hz, 1 H), 6.92 (d, J=5.20 Hz, 1 H), 3.87 (s, 3 H), 2.57 (s, 3 H).

Step 2: 5-tert-Butyl-3-methyl-thiophene-2-carboxylic acid methyl ester

A mixture of AICI₃ (17.3 g, 130 mmol) and CH₂Cl₂ (20 mL) under argon was cooled to -78 °C. A solution of methyl 3-methylthiophene-2-carboxylate (13.5 g, 86.4 mmol) in CH₂Cl₂ (10 mL) was added dropwise over 5 minutes. The reaction mixture was stirred at -78 °C for 5 minutes. A solution of 2-chloro-2-methylpropane (available from Aldrich; 9.9 mL, 90.7 mmol) in CH₂Cl₂ (10 mL) was added dropwise to the cold reaction mixture over 30 min. The reaction mixture was allowed to warm to room temperature and stir overnight. The reaction mixture was then poured into ice-water. The organic phase was separated, dried (Na₂SO₄), filtered, and concentrated. The residue was purified by chromatography (silica gel, 0-5% EtOAc/hexanes) to give 5-tert-butyl-3-methyl-thiophene-2-carboxylic acid methyl ester (7.05 g, 38%) as a yellow oil. H NMR (300 MHz, CDCls) δ ppm 6.68 (s, 1 H), 3.84 (s, 3 H), 2.50 (s, 3 H), 1.38 (s, 9 H).

Step 3: 3-Bromomethyl-5-tert-butyl-thiophene-2-carboxylic acid methyl ester

A mixture of 3-methyl-thiophene-2-carboxylic acid methyl ester (6.06 g, 28.5 mmol), N-
bromosuccinimide (6.1 g, 34.3 mmol), AIBN (234 mg, 1.43 mmol) and CC1₄ (80 mL) was heated at 90 °C overnight. The reaction mixture was cooled, and filtered. The filtrate was concentrated and the residue was purified by chromatography (silica gel, 5% EtOAc/hexanes) to give 3-bromomethyl-5-tert-butyl-thiophene-2-carboxylic acid methyl ester (2.65 g, 32%) as a
yellow oil. Mixed fractions from the first column were concentrated and purified by chromatography (silica gel, 5% EtOAc/hexanes) to give 3-bromomethyl-5-tert-butyl-thiophene-2-carboxylic acid methyl ester (2.54 g, 30%). H NMR (300 MHz, CDCl₃) δ ppm 6.93 (s, 1 H), 4.87 (s, 2 H), 3.88 (s, 3 H), 1.39 (s, 8 H).

5 Step 4: 5-tert-Butyl-3-([2-fluoro-4-[2-methoxy-6-(1-methyl-1H-pyrazol-4-yl)-pyridin-4-yl]-benzylamino]-methyl)-thiophene-2-carboxylic acid methyl ester

A mixture of 3-bromomethyl-5-tert-butyl-thiophene-2-carboxylic acid methyl ester (130 mg, 446 µmol), 2-fluoro-4-[2-methoxy-6-(l -methyl-1H-pyrazol-4-yl)-pyridin-4-yl]-benzylamine (which may be prepared as described in the Synthesis of Intermediate section above; 0.375 g, 1.2 mmol), Cs₂CO₃ (390 mg, 1.2 mmol), and acetonitrile (7 mL) was stirred over the weekend at room temperature. The reaction mixture was filtered and the mixture was concentrated over silica gel. The residue was loaded onto an 80 g silica gel column and the column was eluted 50-100% EtOAc/hexanes to give 5-tert-butyl-3-([2-fluoro-4-[2-methoxy-6-(1-methyl-1H-pyrazol-4-yl)-pyridin-4-yl]-benzylamino]-methyl)-thiophene-2-carboxylic acid methyl ester (60 mg, 26%) as a colorless oil. MS calcd. for a C₂₈H₃₂FN₄O₃S [(M+H)⁺] 523, obsd. 523.3.
Step 5: 5-tert-Butyl-3-(2-fluoro-4-[2-methoxy-6-(1-methyl-1H-pyrazol-4-yl)-pyridin-4-yl]-benzylamino)-methyl)-thiophene-2-carboxylic acid

A mixture of 5-tert-butyl-3-(2-fluoro-4-[2-methoxy-6-(1-methyl-1H-pyrazol-4-yl)-pyridin-4-yl]-benzylamino)-methyl)-thiophene-2-carboxylic acid methyl ester (60 mg, 115 µmol), lithium hydroxide monohydrate (25.3 mg, 574 µmol), THF (1 mL) and water (1 mL) was heated at 60 °C for 18 h. The reaction mixture was cooled to room temperature and the THF was evaporated. Water (10 mL) was added. Aqueous 1 M HCl was added until a white suspension formed. The mixture was extracted with EtOAc and the organic extract was dried (Na₂SO₄), filtered, and evaporated to give 5-tert-butyl-3-(2-fluoro-4-[2-methoxy-6-(1-methyl-1H-pyrazol-4-yl)-pyridin-4-yl]-benzylamino)-methyl)-thiophene-2-carboxylic acid (45 mg, 77%) as a white solid. MS calcd. for C₂₇H₃₀FN₄O₃S [(M+H)+] 509, obsd. 509.3. The crude product was taken onto the next step without further purification.

Step 6: 2-tert-Butyl-5-[2-fluoro-4-[2-methoxy-6-(1-methyl-1H-pyrazol-4-yl)-pyridin-4-yl]-benzyl]-4,5-dihydro-thieno[2,3-c]pyrrol-6-one

A mixture of 5-tert-butyl-3-(2-fluoro-4-[2-methoxy-6-(1-methyl-1H-pyrazol-4-yl)-pyridin-4-yl]-benzylamino)-methyl)-thiophene-2-carboxylic acid (45 mg, 88.5 µmol), PYBOP (60 mg,
115 \mu\text{mol}, DIPEA (50 \mu\text{L}, 286 \mu\text{mol}), and DMF (2.0 mL) was stirred overnight at room temperature. The solvent was evaporated under a stream of nitrogen. EtOAc (10 mL) was added and the solution was washed with saturated aqueous NaHCO$_3$. The organic phase was dried (Na$_2$SO$_4$), filtered, and evaporated to give 2-tert-butyl-5-{2-fluoro-4-[2-methoxy-6-(1-methyl-1H-pyrazol-4-yl)-pyridin-4-yl]-benzyl}-4,5-dihydro-thieno[2,3-c]pyrrol-6-one (77 mg, 177%).

MS calcd. for C$_{27}$H$_{26}$F$_4$O$_2$S [(M+H)$^+$] 491, obsd. 491.3. The crude product was used in the next step without further purification.

**Step 7: 2-tert-Butyl-5-{2-fluoro-4-[6-(1-methyl-1H-pyrazol-4-yl)-2-oxo-1,2-dihydro-pyridin-4-yl]-benzyl}-4,5-dihydro-thieno [2,3-c]pyrrol-6-one**

A mixture of crude 2-tert-butyl-5-{2-fluoro-4-[2-methoxy-6-(1-methyl-1H-pyrazol-4-yl)-pyridin-4-yl]-benzyl}-4,5-dihydro-thieno[2,3-c]pyrrol-6-one (crude, from Step 6; 77 mg, approx. 88.5 \mu\text{mol}), trimethylsilyl chloride (40 \mu\text{L}, 0.32 mmol) and Nal (47 mg, 0.31 mmol) in CH$_3$CN (2 mL) was heated at 80 °C for 2 h and then cooled to room temperature. EtOAc (10 mL) was added, followed by 1 M aqueous Na$_2$S$_2$O$_3$ solution (5 mL) was added, followed by saturated aqueous NaHCO$_3$ (2 mL). The organic phase was dried (Na$_2$SO$_4$), filtered, and evaporated. The residue was purified by chromatography (silica gel, 0-5% MeOH/CH$_2$Cl$_2$ with 1% NH$_4$OAc) to give 2-tert-butyl-5-{2-fluoro-4-[6-(1-methyl-1H-pyrazol-4-yl)-2-oxo-1,2-dihydro-pyridin-4-yl]-benzyl}-4,5-dihydro-thieno[2,3-c]pyrrol-6-one (35 mg, 47%) as a light yellow powder. MS calcd. for C$_{26}$H$_{28}$FN$_4$O$_2$S [(M+H)$^+$] 477, obsd. 477.2. H NMR (300 MHz, DMSO-d$_6$) δ ppm 11.75 (s, 2 H), 8.42 (s, 1 H), 8.16 (s, 1 H), 7.57 - 7.73 (m, 3 H), 7.37 (t, $J$=8.1 Hz, 1 H), 7.03 (s, 1 H), 6.47 (br. s., 1 H), 5.76 (s, 1 H), 4.75 (s, 2 H), 4.33 (s, 2 H), 3.88 (s, 3 H), 2.96 - 3.06 (m, 3 H), 1.73 (t, $J$=6.5 Hz, 3 H), 1.37 (s, 9 H).
Biological Examples

**Bruton's tyrosine kinase (Btk) inhibition Assay**

The assay is a capture of radioactive $^{33}$P phosphorylated product through filtration. The interactions of Btk, biotinylated SH$_2$ peptide substrate (Src homology), and ATP lead to phosphorylation of the peptide substrate. Biotinylated product is bound streptavidin sepharose beads. All bound, radiolabeled products are detected by scintillation counter.

Plates assayed are 96-well polypropylene (Greiner) and 96-well 1.2 µl hydrophilic PVDF filter plates (Millipore). Concentrations reported here are final assay concentrations: 10-100 µM compounds in DMSO (Burdick and Jackson), 5-10 nM Btk enzyme (His-tagged, full-length), 30 µM peptide substrate (Biotin-Aca-AAAEEIYGEI-NH$_2$), 100 µM ATP (Sigma), 8 mM imidazole (Sigma, pH 7.2), 8 mM glycerol-2-phosphate (Sigma), 200 µM EGTA (Roche Diagnostics), 1 mM MnCl$_2$ (Sigma), 20 mM MgCl$_2$ (Sigma), 0.1 mg/ml BSA (Sigma), 2 mM DTT (Sigma), 1 µCi $^{33}$P ATP (Amersham), 20% streptavidin sepharose beads (Amersham), 50 mM EDTA (Gibco), 2 M NaCl (Gibco), 2 M NaCl w/ 1% phosphoric acid (Gibco), microscint-20 (Perkin Elmer).

IC$_{50}$ determinations are calculated from 10 data points per compound utilizing data produced from a standard 96-well plate assay template. One control compound and seven unknown inhibitors were tested on each plate and each plate was run twice. Typically, compounds were diluted in half-log starting at 100 µM and ending at 3 nM. The control compound was staurosporine. Background was counted in the absence of peptide substrate. Total activity was determined in the presence of peptide substrate. The following protocol was used to determine Btk inhibition.

1) Sample preparation: The test compounds were diluted at half-log increments in assay buffer (imidazole, glycerol-2-phosphate, EGTA, MnCl$_2$, MgCl$_2$, BSA).

2) Bead preparation

   a.) rinse beads by centrifuging at 500 g

   b.) reconstitute the beads with PBS and EDTA to produce a 20% bead slurry
3) Pre-incubate reaction mix without substrate (assay buffer, DTT, ATP, $^{33}$P ATP) and mix with substrate (assay buffer, DTT, ATP, $^{33}$P ATP, peptide substrate) 30°C for 15 min.

4) To start assay, pre-incubate 10 μL Btk in enzyme buffer (imidazole, glycerol-2-phosphate, BSA) and 10 μL of test compounds for 10 min at RT.

5) Add 30 μL reaction mixture without or with substrate to Btk and compounds.

6) Incubate 50 μL total assay mix for 30 min at 30°C.

7) Transfer 40 μL of assay to 150 μL bead slurry in filter plate to stop reaction.

8) Wash filter plate after 30 min, with following steps

   a. 3 x 250 μL NaCl

   b. 3 x 250 μL NaCl containing 1% phosphoric acid

   c. 1 x 250 μL H$_2$O

9) Dry plate for 1 h at 65°C or overnight at RT

10) Add 50 μL microscint-20 and count $^{33}$P cpm on scintillation counter.

**Calculate percent activity from raw data in cpm**

\[
\text{percent activity} = \frac{(\text{sample} - \text{bkg})}{(\text{total activity} - \text{bkg})} \times 100
\]

**Calculate IC$_{50}$ from percent activity, using one-site dose response sigmoidal model**

\[
y = A + \left(\frac{(B - A)}{1 + \left(\frac{x}{C}\right)^D}\right)
\]

\[
x = \text{cmpd cone}, \ y = \% \text{ activity}, \ A = \text{min}, \ B = \text{max}, \ C = \text{IC}_{50}, \ D = 1 \text{ (hill slope)}
\]

**Bruton's tyrosine kinase (BTK) inhibition TR-FRET (Time resolved FRET) assay**

This BTK competition assay measures compound potency (IC50) for the inactivated state of Bruton's Tyrosine Kinase using FRET (Forster/Fluorescence Resonance Energy Transfer) technology. The BTK - Eu complex was incubated on ice one hour prior to use at a starting concentration of 50 nM BTK-Bioease™ : 10 nM Eu-streptavidin (Perkin-Elmer Catalog#
AD0062). The assay buffer consisted of 20 mM HEPES (pH 7.15), 0.1 mM DTT, 10 mM MgCl$_2$, 0.5 mg/ml BSA with 3% Kinase Stabilizer (Fremont Biosolutions, Catalog # STB-K02). After 1h, the reaction mixture from above was diluted 10 fold in assay buffer to make 5 nM BTK: InM Eu-Streptavidin complex (donor fluorophore). 18µl of a mixture of 0.11 nM BTK-Eu and 0.11 nM Kinase Tracer 178 (Invitrogen, Catalog # PV5593,) with BTK-Eu alone as a negative control, was then dispensed into 384-well flat bottom plates (Greiner, 784076). Compounds to be tested in assay were prepared as 10x concentrations and serial dilution in half-log increments was performed in DMSO so as to generate 10 point curves. To initiate the FRET reaction, compounds prepared as 10x stock in DMSO was added to the plates and the plates were incubated 18-24h at 14°C.

After the incubation the plates were read on a BMG Pherastar Fluorescent plate reader (or equivalent) and used to measure the emission energy from the europium donor fluorophore (620 nm emission) and the FRET (665 nm emission). The negative control well values were averaged to obtain the mean minimum. The positive "no inhibitor" control wells were averaged to obtain the mean maximum. Percent of maximal FRET was calculated using following equation:

\[
\% \text{ max } \text{FRET} = 100 \times \frac{(\text{FSR}_{\text{cmp d}} - \text{FSR}_{\text{mea min}})}{(\text{FSR}_{\text{mea max}} - \text{FSR}_{\text{mea min}})}
\]

where FSR = FRET Signal ratio. % Max FRET curves were plotted in Activity Base (Excel) and the IC50 (%), hill slope, z’ and %CV were determined. The mean IC50 and standard deviation will be derived from duplicate curves (singlet inhibition curves from two independent dilutions) using Microsoft Excel.

Representative compound data for this assay are listed below in Table II.

**TABLE II.**

<table>
<thead>
<tr>
<th>Compound</th>
<th>FRET IC50 (µM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>I-1</td>
<td>3.31909</td>
</tr>
<tr>
<td>1-2</td>
<td>0.98277</td>
</tr>
<tr>
<td>1-3</td>
<td>0.36577</td>
</tr>
<tr>
<td>1-4</td>
<td>13.31457</td>
</tr>
</tbody>
</table>
Inhibition of B cell activation in whole blood measured by CD69 expression

A procedure to test the ability of Btk inhibitors to suppress B cell receptor-mediated activation of B cells in human blood is as follows:

Human whole blood (HWB) is obtained from healthy volunteers, with the following restrictions: 24 hr drug-free, non-smokers. Blood is collected by venipuncture into Vacutainer tubes anticoagulated with sodium heparin. Test compounds are diluted to ten times the desired starting drug concentration in PBS (20x), followed by three-fold serial dilutions in 10% DMSO in PBS to produce a nine point dose-response curve. 5.5 µl of each compound dilution is added in duplicate to a 2ml 96-well V bottom plate (Analytical Sales and Services, #59623-23); 5.5 µl of 10% DMSO in PBS is added to control and no-stimulus wells. HWB (100 µl) is added to each well, and after mixing the plates are incubated at 37°C, 5% CO₂, 100% humidity for 30 minutes. Goat F(ab')2 anti-human IgM (Southern Biotech, #2022-14) (10 µl of a 500 µg/ml solution, 50 µg/ml final concentration) is added to each well (except the no-stimulus wells) with mixing and the plates are incubated for an additional 20 hours.

At the end of the 20 hour incubation, samples are incubated with fluorescent-probe-labeled antibodies (15 µl PE Mouse anti-Human CD20, BD Pharmingen, #555623, and/or 20 µl APC Mouse anti-Human CD69, BD Pharmingen #555533) for 30 minutes, at 37°C, 5% CO₂, 100% humidity. Included are induced control, unstained and single stains for compensation adjustments and initial voltage settings. Samples are then lysed with 1ml of IX Pharmingen Lyse Buffer (BD Pharmingen # 555899), and plates are centrifuged at 1800 rpm for 5 minutes. Supernatants are removed via suction and the remaining pellets are lysed again with another 1ml of IX Pharmingen Lyse Buffer, and plates are spun down as before. Supernatants
are aspirated and remaining pellets are washed in FACs buffer (PBS + 1% FBS). After a final spin, the supernantants are removed and pellets are resuspended in 180µl of FACs buffer. Samples are transferred to a 96 well plate suitable to be run on the HTS 96 well system on the BD LSR II flow cytometer.

Using appropriate excitation and emission wavelengths for the fluorophores used, data are acquired and percent positive cell values are obtained using Cell Quest Software. Results are initially analyzed by FACS analysis software (FlowJo). The IC50 for test compounds is defined as the concentration which decreases by 50% the percentage of CD69-positive cells that are also CD20-positive after stimulation by anti-IgM (average of 8 control wells, after subtraction of the average of 8 wells for the no-stimulus background). The IC50 values are calculated using XLfit software version 3, equation 201.

**Inhibition of B-cell Activation - B cell FLIPR assay in Ramos cells**

Inhibition of B-cell activation by compounds of the present invention is demonstrated by determining the effect of the test compounds on anti-IgM stimulated B cell responses.

The B cell FLIPR assay is a cell based functional method of determining the effect of potential inhibitors of the intracellular calcium increase from stimulation by an anti-IgM antibody. Ramos cells (human Burkitt's lymphoma cell line, ATCC-No. CRL-1596) were cultivated in Growth Media (described below). One day prior to assay, Ramos cells were resuspended in fresh growth media (same as above) and set at a concentration of 0.5 x 10^6/mL in tissue culture flasks. On day of assay, cells are counted and set at a concentration of 1 x 10^6/mL in growth media supplemented with 1µM FLUO-3AM (TefLabs Cat-No. 0116, prepared in anhydrous DMSO and 10%, Pluronic acid) in a tissue culture flask, and incubated at 37°C (4% C0_2) for one h. To remove extracellular dye, cells were collected by centrifugation (5min, 1000 rpm), resuspended in FLIPR buffer (described below) at 1 x 10^6 cells/mL and then dispensed into 96-well poly-D-lysine coated black/clear plates (BD Cat-No. 356692) at 1 x 10^5 cells per well. Test compounds were added at various concentrations ranging from 100 µM to 0.03 µM (7 concentrations, details below), and allowed to incubate with cells for 30 min at RT. Ramos cell Ca^{2+} signaling was stimulated by the addition of 10 µg/mL anti-IgM (Southern Biotech, Cat-No. 2020-01) and measured on a FLIPR (Molecular Devices, captures images of 96 well plates using a CCD camera with an argon laser at 480nM excitation).
Media/Buffers:

Growth Medium: RPMI 1640 medium with L-glutamine (Invitrogen, Cat-No. 61870-010), 10% Fetal Bovine Serum (FBS, Summit Biotechnology Cat-No. FP-100-05); 1mM Sodium Pyruvate (Invitrogen Cat. No. 11360-070).

FLIPR buffer: HBSS (Invitrogen, Cat-No. 14175-079), 2mM CaCl₂ (Sigma Cat-No. C-4901), HEPES (Invitrogen, Cat-No. 15630-080), 2.5mM Probenecid (Sigma, Cat-No. P-8761), 0.1% BSA (Sigma, Cat-No. A-7906), 1mM Glucose (Sigma, Cat-No.G-7528)

Compound dilution details:

In order to achieve the highest final assay concentration of 100 µM, 24 µL of 10 mM compound stock solution (made in DMSO) is added directly to 576 µL of FLIPR buffer. The test compounds are diluted in FLIPR Buffer (using Biomek 2000 robotic pipettor) resulting in the following dilution scheme: vehicle, 1.00 x 10⁻⁴ M, 1.00 x 10⁻³, 3.16 x 10⁻², 1.00 x 10⁻¹, 3.16 x 10⁻⁷, 1.00 x 10⁻⁷, 3.16 x 10⁻⁸.

Assay and Analysis:

Intracellular increases in calcium were reported using a max - min statistic (subtracting the resting baseline from the peak caused by addition of the stimulatory antibody using a Molecular Devices FLIPR control and statistic exporting software. The IC₅₀ was determined using a non-linear curve fit (GraphPad Prism software).

**Mouse Collagen-induced arthritis (mCIA)**

On day 0 mice are injected at the base of the tail or several spots on the back with an emulsion of Type II Collagen (i.d.) in Complete Freund's adjuvant (CFA). Following collagen immunization, animals will develop arthritis at around 21 to 35 days. The onset of arthritis is synchronized ( boosted) by systemic administration of collagen in Incomplete Freund's adjuvant (IFA; i.d.) at day 21. Animals are examined daily after day 20 for any onset of mild arthritis (score of 1 or 2; see score description below) which is the signal to boost. Following boost, mice are scored and dosed with candidate therapeutic agents for the prescribed time ( typically 2-3 weeks) and dosing frequency, daily (QD) or twice-daily (BID).
Rat Collagen-induced arthritis (rCIA)

On day 0, rats are injected with an emulsion of Bovine Type II Collagen in Incomplete Freund's adjuvant (IFA) is injected intradermally (i.d.) on several locations on the back. A booster injection of collagen emulsion is given around day 7, (i.d.) at the base of the tail or alternative sites on the back. Arthritis is generally observed 12-14 days after the initial collagen injection. Animals may be evaluated for the development of arthritis as described below (Evaluation of arthritis) from day 14 onwards. Animals are dosed with candidate therapeutic agents in a preventive fashion starting at the time of secondary challenge and for the prescribed time (typically 2-3 weeks) and dosing frequency, daily (QD) or twice-daily (BID).

Evaluation of Arthritis:

In both models, developing inflammation of the paws and limb joints is quantified using a scoring system that involves the assessment of the 4 paws following the criteria described below:

Scoring:  
1= swelling and/or redness of paw or one digit.
2= swelling in two or more joints.
3= gross swelling of the paw with more than two joints involved.
4= severe arthritis of the entire paw and digits.

Evaluations are made on day 0 for baseline measurement and starting again at the first signs or swelling for up to three times per week until the end of the experiment. The arthritic index for each mouse is obtained by adding the four scores of the individual paws, giving a maximum score of 16 per animal.

Rat In Vivo Asthma Model

Male Brown-Norway rats are sensitized i.p. with 100 µg of OA (ovalbumin) in 0.2 ml alum once every week for three weeks (day 0, 7, and 14). On day 21 (one week following last sensitization), the rats are dosed q.d. with either vehicle or compound formulation subcutaneously 0.5 hour before OA aerosol challenge (1% OA for 45 minutes) and terminated 4 or 24 hours after challenge. At time of sacrifice, serum and plasma are collected from all animals for serology and PK, respectively. A tracheal cannula is inserted and the lungs are lavaged 3X with PBS. The BAL fluid is analyzed for total leukocyte number and differential leukocyte counts. Total
leukocyte number in an aliquot of the cells (20-100 µl) is determined by Coulter Counter. For differential leukocyte counts, 50-200 µl of the sample is centrifuged in a Cytospin and the slide stained with Diff-Quik. The proportions of monocytes, eosinophils, neutrophils and lymphocytes are counted under light microscopy using standard morphological criteria and expressed as a percentage. Representative inhibitors of Btk show decreased total leucocyte count in the BAL of OA sensitized and challenged rats as compared to control levels.

The foregoing invention has been described in some detail by way of illustration and example, for purposes of clarity and understanding. It will be obvious to one of skill in the art that changes and modifications may be practiced within the scope of the appended claims. Therefore, it is to be understood that the above description is intended to be illustrative and not restrictive. The scope of the invention should, therefore, be determined not with reference to the above description, but should instead be determined with reference to the following appended claims, along with the full scope of equivalents to which such claims are entitled.

All patents, patent applications and publications cited in this application are hereby incorporated by reference in their entirety for all purposes to the same extent as if each individual patent, patent application or publication were so individually denoted.
Claims

1. A compound of Formula I,

   \[ \text{I} \]

   wherein:

5  A is unsaturated or partially saturated monocyclic or bicyclic heteroaryl or phenyl, optionally substituted with one or more A';

   A' is halo, lower alkyl, or oxo;

   each R is independently halo, hydroxyl lower alkyl, or lower alkyl;

   m is 0, 1, or 2;

10  R is methyl pyrazolyl;

   n is 0 or 1; and

   X is a bond, CH or NHC(=0);

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1, wherein X is CH.

3. The compound of claim 1 or 2, wherein n is 1.

4. The compound of claim 1 or 2, wherein n is 0.

5. The compound of any one of claims 1-4, wherein m is 0.
6. The compound of any one of claims 1-4, wherein m is 1.

7. The compound of any one of claims 1-6, wherein R¹ is F.

8. The compound of any one of claims 1-6, wherein R¹ is hydroxyl lower alkyl.

9. The compound of any one of claims 1-4, wherein m is 2.

10. The compound of claim 9, wherein both R¹ are F.

11. The compound of claim 9, wherein one R¹ is F and the other is hydroxyl lower alkyl.

12. The compound of any one of claims 1-11, wherein A is unsaturated or partially saturated monocyclic heteroaryl, optionally substituted with one or more A'.

13. The compound of any one of claims 1-11, wherein A is unsaturated or partially saturated bicyclic heteroaryl, optionally substituted with one or more A'.

14. The compound of claim 12 or 13, wherein A' is F, oxo, or tert-butyl.

15. The compound of any one of claims 1-14 selected from the group consisting of:

6-tert-Butyl-8-fluoro-2-[4-(2-oxo-1,2-dihydro-pyridin-4-yl)-benzyl]-2 H-phthalazin-1-one;

6-tert-Butyl-8-fluoro-2-[2-fluoro-4-(2-oxo-1,2-dihydro-pyridin-4-yl)-benzyl]-2 H-phthalazin-1-one;

6-tert-Butyl-8-fluoro-2-[2-hydroxymethyl-3-(2-oxo-1,2-dihydro-pyridin-4-yl)-phenyl]-2 H-phthalazin-1-one;

6-tert-Butyl-2-[2,6-difluoro-4-(2-oxo-1,2-dihydro-pyridin-4-yl)-benzyl]-8-fluoro-2 H-phthalazin-1-one;

6-tert-Butyl-8-fluoro-2-[2-hydroxymethyl-4-(2-oxo-1,2-dihydro-pyridin-4-yl)-benzyl]-2 H-phthalazin-1-one;

6-tert-Butyl-8-fluoro-2- {2-fluoro-4-[6-(1-methyl-1H-pyrazol-4-yl)-2-oxo-1,2-dihydro-pyridin-4-yl]-benzyl} -2 H-phthalazin-1-one;
4-tert-Butyl-N-[2-methyl-3-(2-oxo-1,2-dihydro-pyridin-4-yl)-phenyl]-benzamide;

6-tert-Butyl-8-fluoro-2-[3-hydroxymethyl-4-(2-oxo-1,2-dihydro-pyridin-4-yl)-benzyl]-2\(H\)-phthalazin-1-one;

6-tert-Butyl-8-fluoro-2-[2-fluoro-5-hydroxymethyl-4-(2-oxo-1,2-dihydro-pyridin-4-yl)-benzyl]-2\(H\)-phthalazin-1-one; and

2-tert-Butyl-5-{2-fluoro-4-[6-(1-methyl-1\(H\)-pyrazol-4-yl)-2-oxo-1,2-dihydro-pyridin-4-yl]-benzyl}-4,5-dihydro-thieno[2,3-c]pyrrol-6-one.

16. A method for treating an inflammatory and/or autoimmune condition comprising administering to a patient in need thereof a therapeutically effective amount of the compound of any one of claims 1-15.

17. A method for treating an inflammatory condition comprising administering to a patient in need thereof a therapeutically effective amount of the compound of any one of claims 1-15.

18. A method for treating rheumatoid arthritis comprising administering to a patient in need thereof a therapeutically effective amount of the compound of any one of claims 1-15.

19. A method for treating asthma comprising administering to a patient in need thereof a therapeutically effective amount of the compound of any one of claims 1-15.

20. A pharmaceutical composition comprising the compound of any one of claims 1-15, admixed with at least one pharmaceutically acceptable carrier, excipient or diluent.

21. The use of the compound of any one of claims 1-15 for use as therapeutically active substance.

22. The use of the compound of any one of claims 1-15 for the preparation of a medicament for the treatment of an inflammatory and/or autoimmune condition.

23. The use of the compound of any one of claims 1-15 for the treatment of an inflammatory and/or autoimmune condition.

24. The compound of any one of claims 1-15 for use in the treatment of an inflammatory and/or autoimmune condition.
25. The invention as hereinbefore described.
### INTERNATIONAL SEARCH REPORT

**A. CLASSIFICATION OF SUBJECT MATTER**

INV. C07D401/10 C07D401/12 C07D495/04 C07D211/82 A61K31/4412 A61K31/502 A61K31/407 A61P19/02 A61P29/02

**ADD.**

According to International Patent Classification (IPC) or both national classification and IPC

### B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, WPI Data, CHEM ABS Data, BEI LSTEIN Data

### C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>WO 2012/020008 AI (HOFFMANN LA ROCHE [CH]; BERTHEL STEVEN JOSEPH [US]; BI LLEDEAU ROLAND J) 16 February 2012 (2012-02-16) page 268; claim 1</td>
<td>1-25</td>
</tr>
<tr>
<td>A</td>
<td>WO 2012/031004 AI (GI LEAD CONNECTICUT INC [US]; GENENTECH INC [US]; CURRI E KEVIN S [US];) 8 March 2012 (2012-03-08) page 127; claim 1 page 132; claim 20</td>
<td>1-25</td>
</tr>
<tr>
<td>A</td>
<td>WO 2010/100070 AI (HOFFMANN LA ROCHE [CH]; BERTHEL STEVEN JOSEPH [US]; FI R00ZNIA FARIBORZ) 10 September 2010 (2010-09-10) page 260; claim 1 page 268; claims 24-25</td>
<td>1-25</td>
</tr>
</tbody>
</table>

* Further documents are listed in the continuation of Box C.

* Special categories of cited documents:

- **A** document defining the general state of the art which is not considered to be of particular relevance
- **E** earlier application or patent but published on or after the international filing date
- **L** document which may throw doubts on priority claim(s) or which establishes the publication date of another citation or other special reason (as specified)
- **O** document referring to an oral disclosure, use, exhibition or other means
- **P** document published prior to the international filing date but later than the priority date claimed

- **T** later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- **X** document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- **Y** document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- **Z** document member of the same patent family

### Date of the actual completion of the international search

9 December 2013

### Date of mailing of the international search report

16/12/2013

Name and mailing address of the ISA:

European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016

Authorized officer:

Jeanjean, Fabien
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>WO 2009/098144 HOFFMANN LA ROCHE [CH]; DEWDNEY NOLAN JAMES [US]; KENNEDY-SMITH JOSHUA 13 August 2009 (2009-08-13) page 90; claim 1 page 92; claims 12, 14</td>
<td>1-25</td>
</tr>
<tr>
<td>X</td>
<td>JP 10 045750 TAKEDA CHEM IND LTD 17 February 1998 (1998-02-17)</td>
<td>1, 4, 5, 12, 20, 25</td>
</tr>
<tr>
<td>A</td>
<td>page 10; compounds 11-15</td>
<td>2, 3, 6-11, 13-19, 21-24</td>
</tr>
<tr>
<td>A</td>
<td>page 16; compound A H (VI)</td>
<td>6-11, 13-19, 21-24</td>
</tr>
<tr>
<td>Patent document cited in search report</td>
<td>Publication date</td>
<td>Patent family member(s)</td>
</tr>
<tr>
<td>---------------------------------------</td>
<td>------------------</td>
<td>--------------------------</td>
</tr>
<tr>
<td>wo 2012020008</td>
<td>Al 16-02-2012</td>
<td>AR 082590 AI</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 2011288489 AI</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2807634 AI</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 103153984 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CO 6620025 A2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EA 201390207 AI</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 2603500 AI</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2013533300 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>KR 20130038420 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>MA 34465 Bl</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PE 11532013 AI</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SG 187747 AI</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2012040949 AI</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2013178461 AI</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wo 2012020008 AI</td>
</tr>
</tbody>
</table>

| wo 2012031004                          | Al 08-03-2012    | CA 2809836 AI            | 08-03-2012      |
|                                       |                  | CN 103189369 A           | 03-07-2013      |
|                                       |                  | EP 2611790 AI            | 10-07-2013      |
|                                       |                  | JP 2013536863 A          | 26-09-2013      |
|                                       |                  | KR 20130101044 A         | 12-09-2013      |
|                                       |                  | US 2013281432 AI         | 24-10-2013      |
|                                       |                  | Wo 2012031004 AI         | 08-03-2012      |

| wo 2010100070                          | Al 10-09-2010    | AR 076066 AI             | 18-05-2011      |
|                                       |                  | AU 2010220435 AI         | 18-08-2011      |
|                                       |                  | CA 2753341 AI            | 10-09-2010      |
|                                       |                  | CN 102341383 A           | 01-02-2012      |
|                                       |                  | EP 2403846 AI            | 11-01-2012      |
|                                       |                  | JP 2012519200 A          | 23-08-2012      |
|                                       |                  | KR 20110011325 A         | 10-10-2011      |
|                                       |                  | PE 00812012 AI           | 06-02-2012      |
|                                       |                  | RU 2011140064 A          | 10-04-2013      |
|                                       |                  | SG 173816 AI             | 29-09-2011      |
|                                       |                  | TW 201035072 A           | 01-10-2010      |
|                                       |                  | US 2010222325 AI         | 02-09-2010      |
|                                       |                  | Wo 2010100070 AI         | 10-09-2010      |

<p>| wo 2009098144                          | Al 13-08-2009    | AR 070408 AI             | 07-04-2010      |
|                                       |                  | AU 2009211514 AI         | 13-08-2009      |
|                                       |                  | CA 2710462 AI            | 13-08-2009      |
|                                       |                  | CN 101932573 A           | 29-12-2010      |
|                                       |                  | CO 6290767 A2            | 20-06-2011      |
|                                       |                  | CR 11598 A               | 27-10-2010      |
|                                       |                  | DK 2242749 T3            | 17-06-2013      |
|                                       |                  | EC SP10010384 A          | 30-09-2010      |
|                                       |                  | EP 2242749 AI            | 27-10-2010      |
|                                       |                  | ES 2420846 T3            | 27-08-2013      |
|                                       |                  | HR P20130815 T1          | 31-06-2013      |
|                                       |                  | JP 5299739 B2            | 07-08-2013      |
|                                       |                  | JP 2011511027 A          | 07-04-2011      |
|                                       |                  | KR 20100993130 A         | 24-08-2010      |
|                                       |                  | NZ 586916 A              | 29-06-2012      |
|                                       |                  | PE 14842009 AI           | 03-10-2009      |
|                                       |                  | PT 2242749 E             | 16-07-2013      |
|                                       |                  | RU 2010136665 A          | 20-03-2012      |
|                                       |                  | TW 200938538 A           | 16-09-2009      |
|                                       |                  | Wo 2009098144 AI         | 13-08-2009      |</p>
<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td>JP 10045750 A</td>
<td>17-02-1998</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>